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Abstract
Cerebral accumulation of amyloidogenic protein aggregates is most frequently observed
in the pathogenesis of neurodegenerative diseases. Recent studies showed prion like spreading of
beta amyloid (Aβ) in Alzheimer’s disease (AD) and α-synuclein protein in Parkinson’s disease
(PD) brain. Failure or compromise to the chaperone activity of protein disulfide isomerase (PDI)
is also been reported as a major factor of aggregate formation. Nitrosative stress mediated Snitrosylation (SNO) of protein disulfide isomerase (PDI), a housekeeping oxidoreductase, has
been implicated in the pathogenesis of sporadic PD and AD. Mitochondrial dysfunction, leading
to elevated levels of reactive oxygen species (ROS), is associated with the pathogenesis of
neurodegenerative disorders and neuronal cell death. Rotenone and MPTP has traditionally been
employed as mitochondrial stressor to induce ROS insult in cell line experiments. In this study,
we have monitored the aggregation of green-fluorescent protein (GFP)-tagged synphilin-1 (a
Parkinsonin biomarker) as a function of rotenone insult. We report that the innate ketone body,
Na-D-β-hydroxybutyrate (NaβHB) reduces markedly the incidence of synphilin-1 aggregation.
Furthermore, both rotenone and MPTP induce caspase-9 and caspase-3 activation leading to
proteolytic cleavage of substrate nuclear poly (ADP-ribose) polymerase (PARP). PARP cleavage
is directly related to apoptotic cell death. Our data reveal that NaβHB also prevents rotenoneinduced caspase-activated apoptotic cell death in dopaminergic SH-SY5Y cells.
Interaction of Aβ (1-42) and α-synuclein has also been speculated in previous studies.
However, the mechanism behind the alleged interaction is not clear. Beta amyloid (25-35)
fragment can induce toxicity as of Aβ (1-42) peptide fragment, and is capable of forming beta
sheet stacked fibril. We hypothesized whether the 25-35 mer can induce α-synuclein and
promotes the interaction between Aβ (25-35) and α-synuclein in SH-SY5Y cell. We found that
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the addition of beta amyloid (25-35) promotes intracellular accumulation of Lewy body (LB)like inclusions (synphilin-1: α-synuclein). We have also found the Aβ (25-35) induces Snitrosylation of PDI, and subsequent increase in Aβ (25-35) and PDI co-localization in SHSY5Y. Together, these results strongly suggest that Aβ (25-35) oligomers aggravate the
formation of LB-like inclusions through posttranslational modification of PDI, highlighting PDI
as a potential therapeutic target of neurodegenerative diseases.
Previous cell line studies have indicated that SNO-PDI formation provokes synphilin-1
aggregation, the minor Parkinsonian biomarker protein. Yet no work exists investigating whether
SNO-PDI induces α-synuclein aggregation, the major Lewy body constituent associated with
Parkinson’s pathogenesis. Here, we report that SNO-PDI formation is linked to the aggregation
of α-synuclein and also provokes α-synuclein:synphilin-1 deposits (Lewy body-like debris)
normally found in the PD brain. Furthermore, we have examined the ability of a small molecule,
2,3,7,8-Tetrahydroxy-chromeno[5,4,3-cde]chromene-5,10-dione (ellagic acid; EA) to scavenge
NOx radicals and to protect cells from SNO-PDI formation via rotenone insult both, cell-based
and cell-independent in vitro experiments. Furthermore, EA not only mitigates nitrosative-stressinduced aggregation of synphilin-1 but also α-synuclein and α-synuclein:synphilin-1 composites
(Lewy-like neurites) in PC12 cells. Mechanistic analyses of the neuroprotective phenomena
revealed that EA lowered rotenone-instigated reactive oxygen species (ROS) and reactive
nitrogen species (RNS) in PC12 cells, imparted anti-apoptotic tributes and directly interfered
with SNO-PDI formation. Lastly, we demonstrate that EA can bind human serum albumin
(HSA). Together these results collectively indicate that small molecules can provide a
therapeutic foothold for overcoming Parkinson’s through a prophylactic approach.
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CHAPTER 1:

1

Introduction
1.1 Frequency and distribution of neurodegenerative disease
Deeper understanding of nature through science gave us ability to increase the average
life expectancy rate. As a result, demographics of the older population have been accelerating
dramatically in past few decades. Forty million people aged 65 and over in the United States,
accounted for 13 percent of the total population in 2010. In 2030, the older population is
projected to be twice as large as in 2000, growing from 35 million to 72 million, and
representing nearly 20 percent of the total U.S. population1. Diseases like dementia are of
particular concern among elderly people because the nature of the pathological symptoms that
characterize this condition lead to a loss of independent function, this has a severe impact on
society. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common among all
types of dementia in America2. It is estimated that 5.4 million Americans of all ages had
Alzheimer’s disease in 2012, 5.2 million of these aged 65 and older3 and 200,000 under age 65
who have younger-onset Alzheimer’s4. The Aging, Demographics, and Memory Study
(ADAMS) in 2007 estimated that among 13.9 percent of dementia patients (among people aged
71 or older in America) near about 9.7 percent affected with AD2 and 1.5 million diagnosed as
PD5.
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Copyright © 2012 American Medical Association.
Fig. 1.1. Projected number of persons in US population with Alzheimer disease using the 2000
US Census Bureau middle-series estimates of population growth, bounded by high- and lowseries3.

Fig. 1.2. Prevalence of severe (Mini-Mental State Examination score, ≤9), moderate (10-17), and
mild (≥18) Alzheimer’s disease, in each of three age groups, in the community population
providing data for these estimates3.
3

Copyright © 2012 American Medical Association.

Table 1.1 Current and Projected Number of Persons with Alzheimer Disease (in Millions) Older
Than 65 Years in the US Population by three Age Subgroups*
1.2 Proteins associated with Alzheimer’s disease
Alzheimer’s disease, an irreversible form of dementia characterized by slow decline of
cognitive function, currently affects around 27 million people worldwide. Presently, in the
United States, AD is the sixth leading cause of death which on an average, occurs nine years
after diagnosis6. Pathological findings of human brain’s afflicted with AD confirm the
involvement of extracellular beta-amyloid (Aβ) plaques and hyperphosphorylated intracellular
tau tangles7-12. Alzheimer’s disease can have early or late onset depending on whether it has a
4

familial or sporadic nature, respectively. Mutation of the amyloid precursor protein (APP),
presenelin1&2 (PSEN1 and PSEN2)13,14 and duplication of APP gene15 lead to early onset of
AD. Whereas the etiology behind late onset of AD is attributed to the failure of Aβ-degrading
enzymes and reduced clearance efficiency due to genetic variation in apolipoprotein E (APOE),
PICALM, CR1 and CLU gene16,17.

Fig. 1.3. Balance between APP processing and clearance in a model of AD pathogenesis17.
Beta-amyloid (Aβ)
Cell surface receptor protein APP is the precursor of Aβ as a result of β-secretase and γsecretase activity18. α-secretase and γ-secretase cleave the APP to give rise to the neuroprotective
p3 fragment19. γ-secretase can cut the Aβ amino acid after 38th, 40th or 42nd position and give rise
to less pathological Aβ38 or Aβ40 and neurotoxic Aβ42 isoform19,20. According to the amyloid
cascade hypothesis, increase in the Aβ42/ Aβ40 ratio alter the ionic homeostasis and oxidative
stress, leading to: hyperphosphorylation of tau, tangle formation which ultimately causes axonal
dysfunction, and neuronal cell death21,22.

5

Tau protein
Microtubule associated protein tau is a highly soluble cytoplasmic protein. Tau binds to
tubulin protein during its polymerization into microtubules and gives strength to the neuronal
structure. Hyperphosphorylated tau released from the microtubule results in the collapse of the
neuronal structure and the formation of NFTs, a hallmark histopathological characteristic in AD
patients23-25.

Fig. 1.4. Amyloidogenic Processing Pathway

Fig. 1.5. The Amyloid Cascade Hypothesis26,27
6

1.3 Protein associated with Parkinson’s disease
Parkinson’s disease (PD) is the second most common form of dementia in elderly people,
after AD. The central pathological feature of PD is characterized by progressive and profound
loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), with deposition of
intraneuronal cytoplasmic inclusions termed as Lewy bodies (LB)28. Molecular pathways
responsible for the onset of this disease are still obscure and a matter of debate. It is believed that
PD may result from an environmental factor, a genetic cause, or a combination of the two.
Familial autosomal-dominant type PD is caused by mutations (A53T or A30P) in the gene
SNCA (encoding pre-synaptic protein called α-synuclein)29-31. Neuro-pathological findings of
patients with sporadic PD suggest that α-synuclein found in Lewy bodies may be involved in the
pathogenesis of PD32,33. Synphilin-1 protein, associated with synaptic vesicle34, also interacts
with α-synuclein and might have role play in Lewy body and Lewy neurite (LN) formation35-37.
PARK1 (α-Synuclein)
α-Synuclein (α-syn), a natively unfolded protein of 140 amino acid residues, is important for the
recycling and size regulation of synaptic vesicle38. Structurally, α-syn consists of an N-terminal
amphipathic region, a hydrophobic middle region known as non-amyloid-b component (NAC)
domain, and C-terminal acidic region. PARK1 is the most prevalent among 12 other locus
associated with PD39 because of the hydrophobic NAC domain which tends to aggregate.

Fig. 1.6. Schematic representation of α-synuclein protein.
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Three missense mutations (A53T, A30P and E46K) have been identified so far in α-syn gene4042

. The importance of alpha-synuclein residues 71-82 in the formation of aggregates and

oligomeric species has been proven in flies, whereas the truncated version of α-syn containing
the NAC domain also increased aggregation into large inclusion bodies enhancing dopaminergic
neurotoxicity43. Mechanisms involving abnormal processing and aggregation of α-syn which
disrupts cellular homeostasis, leading towards dopaminergic neurodegeneration, are highly
debated. α-syn aggregates block the normal trafficking between the endoplasmic reticulum (ER)
to the golgi vesicular system leading to ER stress 44. Continuous decrease in dopamine level is a
hallmark sign of PD patients. Results from α-syn knockout mice suggest that α-syn inhibits
dopamine biosynthesis45 and negatively regulates dopaminergic neurotransmission46. These
pathophysiological aspects are detrimental to normal functioning of dopaminergic neurons and
provide implications for disease pathogenesis in α-synuclein-induced PD47.
Synphilin-1
Synphilin-1 is a protein of 919 amino acid residues found in the presynaptic terminal,
suggesting its involvement in neuronal signal transmission48. Synphilin-1 contains six ankyrin
(ANK) repeats (Swiss Protein Database number Q9Y6H5), a coiled-coil domain, and an
ATP/GTP-binding site49. Several research groups showed the involvement of synphilin-1 in
Lewy bodies of PD patients along with α-syn48-50. When synphilin-1 cotransfected with the
NAC portion of α-syn, the formation of eosinophilic inclusion bodies in cultured cells51 was
observed; the interaction between synphilin-1 and α-syn has been confirmed by several groups5254

. Ubiquitinated synphilin-1 has also been shown to interact with Parkin protein trough ankyrin

repeat domain55.

8

Fig. 1.7. Schematic diagram of synphilin-1
Co-expression of synphilin-1, α-synuclein, and Parkin elicits formation of ubiquitin-positive
cytoplasmic inclusions that resemble LBs, suggesting that synphilin-1 might link -synuclein and
Parkin to a common pathogenic mechanism55. A recent report demonstrated that Dorfin, an E3
for mutant superoxide dismutase-1, also interacts with and ubiquitinates synphilin-156.

1.4 Mitochondrial dysfunction and free radicals
Free radicals are chemically very reactive molecules capable of oxidizing different
cellular biomolecules like protein, lipid etc. They are continuously being produced inside cells at
a low concentration due to: the mitochondrial respiratory chain, phagocytosis, ovulation,
fertilization, arachidonic acid synthesis, and many other naturally occurring physiological
processes. Although free radicals are produced in our body for certain functions, high levels of
free radicals can be detrimental to cellular homeostasis. Free radicals can be categorized into two
broad classes: reactive oxygen species (ROS) and reactive nitrogen species (RNS). Ubiquinone
in the mitochondrial electron transfer chain can readily transfer unpaired electrons to oxygen,
which may give rise to superoxide radicals57. Alongside, excessive activation of NMDA type
receptors lead to high release of calcium (Ca2+) ion inside the neuronal cell. At a resting
condition, the Ca2+ ion level is around 100nM, whereas at excitatory state the level can raise
above 1000 nM57. An excessive Ca2+ ion surge activate production the free radicals (e.g., NO*
and ROS), contributing to cell death. Intracellular Ca2+ triggers overexpression of neural nitric
oxide synthase protein in a Ca2+calmodulin (CaM)-dependent manner58.
9

Chronic stimulation of excitatory receptors leads to apoptosis or other forms of cell
death58. Increased levels of neuronal Ca2+ ion can induce the activation of the superoxide
dismutase (SOD) and nitric oxide synthase (NOS) gene leading to subsequent generation of ROS
and RNS 58. The NO* radical plays some vital role in important signal transduction; however, it
also can react with free superoxide radical to form very toxic peroxynitrite (ONOO-).
Peroxynitrite can react with body fluids to form nitrotyrosines, which may lead to neuronal cell
damage and death58. In brain, glial cells and macrophages are the major sources of nitric oxide
(NO2)57. Activation of glial cell and macrophages in neurodegeneration is also an indication
towards the pathogenesis of reactive species. Different diseases as result of increased free radical
production are depicted in Fig. 1.8.

Fig. 1.8. Pathogenesis due to imbalance in free radical formation
10

Among the plethora of known factors associated with the etiology of apoptotic cell death,
nitrosative stress induced cell death by the excessive generation of NO species has been
demonstrated with high importance in recent studies. However, the mechanism underlying this
fact is still unclear. Inhibition of the mitochondrial respiratory chain by rotenone has been widely
used to study the role of the mitochondrial respiratory chain in apoptosis57.

Fig. 1.9. ROS mediated loss of neurotransmission due to mitochondrial dysfunction

Fig. 1.10. Toxicity of dopamine due to oxidative stress. Schematic showing conversion of
dopamine to toxic DA Quinone.
11

Recent studies showed evidence that rotenone and MPTP, both mitochondrial respiratory
chain complex I inhibitors, could induce cell death in a variety of cell types59-63. Since it is been
well established that ROS and RNS play an important role in apoptosis, the molecules that
stimulate formation of these reactive species can result in apoptosis64,65 and a process that can be
inhibited by antioxidants66,67. The mitochondrial derived ROS are vital not only because
mitochondrial respiratory chain components are present in almost all eukaryotic cells, but also
because the ROS produced in mitochondria can readily influence mitochondrial function without
having to cope with long diffusion times from the cytosol. Earlier studies have shown the
mechanism of rotenone-induced apoptosis; rotenone can induce mitochondrial ROS production
and that rotenone-induced mitochondrial ROS production is closely related to rotenone induced
apoptosis68,69. Upon rotenone exposure, the activation of NOX gene has also been speculated58.
Both ROS and RNS are believed to block the complex III, IV and V of mitochondrial electron
transfer chain and thus, inhibit the ATP production process70. In these circumstances the
mitochondria looses its integrity and releases cytochrome c as a signal to initiate the apoptotic
cycle68-71. Release of cytochrome c from the mitochondrial inner membrane space into the
cytosol triggers the autocatalytic processing of procaspase-9 by interacting with Apaf-1.
Caspase-3 gets activated along with other effector caspases by caspase-9, resulting in the
proteolytic cleavage of substrate nuclear poly (ADP-ribose) polymerase (PARP)70. Importantly,
PARP cleavage is directly related to nitrosative stress-mediated cell death along with variety of
apoptotic responses71. In case of chronic rotenone/ MPTP exposure, the consequences on
neuronal cells is lethal and an often found symptom of PD pathogenesis58.

12

1.5 Protein disulfide isomerase (PDI) structure, function and posttranslational modification

Implication of Protein Disulfide Isomerase (PDI; Molecular weight approximately
57kDa), an endoplasmic reticulum resident protein, in maintaining neuronal cell homeostasis is
gaining popularity among the scientific community72. The ubiquitous presence of PDI in all
types of cell is indicative of the importance in folding maturation of newly synthesized proteins
that are destined to transit via the secretory pathway. PDI is part of the thioredoxin super family
and the PDI family of proteins73. Proper perception of PDI function in maintaining disulfide
mediated protein folding is an urgent need for understanding neurodegenerative disease.
PDI is a multi-domain thioredoxin-like (TRX) protein and the active domain composed
of two –CGHC- sequences (Fig. 1.10). There are two “a” type and two “b” type domains in PDI.
The “a” type domains serve as an oxidoreductase catalytic motif whereas the “b” type domains
are implicated for the chaperone-like activity (Fig. 1.10)74.

Structure and function of PDI
Edman and co-workers in 1985 first determined the full amino acid sequence of PDI. The
primary sequence consists of 508 amino acids with a molecular weight of about 57kDa74. At the
N terminal end of PDI sequence there are 19 hydrophobic amino acids, characteristic of a signal
sequence for endoplasmic reticulum localization74. Domain a (7 to 117) and domain a’(348 to
462) show 40% sequence homology whereas b (119-220) and b’(221-332) domain share only
28% of sequence homology (Fig.1.10).
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Fig. 1.11. Schematic diagram of Protein Disulfide Isomerase (PDI). Human and yeast primary
sequence of PDI is compared (A). Catalytic domain “a” represent the oxidoreductase motif and
domain “b” represents the chaperonin motif (B).

PDI is highly abundant in mammalian cells due to the large demand imposed by proteins
that need to attain their functional native structure before being secreted75. In mammalian cells,
PDI is mostly in a reduced state due to the need for disulfide bond shuffling of secreted
proteins75. PDI has two major functions: oxidation of proteins and isomerization of mismatched
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disulfide bonds that can be carried out by PDI because of its own reduced and oxidized states75.
It also participates in protein degradation75.

Oxidation and Isomerization
Correct folding of proteins is essential for functionality; otherwise it can be problematic
to the cellular homeostasis. All the secreted proteins have to go through the ER system for
posttranslational modification. Oxidized PDI transfers its disulfide equivalents to create new
disulfide connection to thiol-containing newly synthesized proteins76. Then the reduced PDI is
recycled by another ER-resident protein, Ero1, which oxidizes the PDI, thereby recycles the
enzyme for another cycle76. PDI functions as an oxidative enzyme, this is illustrated in Fig. 1.11.

Figure 1.12. Schematic diagram of PDI dependent thiol oxidation

Isomerization is another important function of PDI. It can isomerize disulfides by shuffling
existing disulfide bonds of substrates and thereby allowing proteins to acquire their native
diulfide bond. In nascent proteins, the disulfide bond formation can be erroneous: incorrect
disulfide bonds must be broken and corrected for acquiring the native structure76. PDI can
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accelerate the shuffling of disulfide bonds to attain a thermodynamically favorable conformation
in a timely manner76. This mechanism is depicted in Fig. 1.12.

Fig. 1.13. Schematic diagram of PDI dependent thiol isomerization.

1.6 Free-radical stress mediated chemical modification of PDI

So far, we discussed that inhibition of mitochondrial electron transfer chain can trigger
excess production of nitrogen species (NO*) and reactive oxygen species. In the presence of
oxygen and ferrous ions, generation of hydroxyl radicals via the Fenton reaction (Fe2+ +
H2O2→Fe3+ +*OH + -OH), can result in oxidative stress77,78. Reactive nitrogen species (RNS)
also can also react with superoxide to from highly toxic peroxynitrite (ONOO-)57,58.

The

discovery of ROS and RNS as a major transducer molecule in cell help to change our perception
in the field of free radical research. It is now well accepted that free radicals and superoxides
play an important role in cellular homeostasis and ER stress58,78.
Overproduction of ROS and RNS can trigger redox-mediated signaling cascade inside the
cell through the posttranslational modification of free thiols including s-nitrosylation and sglutationylation. This free radical-induced stress can result in posttranslational modification of
16

the active cysteine residue of PDI78. Cysteine residues (Cys) in PDI are labile to protein
oxidation, as they easily can react with NO* and *OH free radicals78. Deprotonated Cys of thiol
group generates the thiolate anion to increase its nucleophilicity and therefore reactivity towards
free radicals77,78. Due to the attack of NO* and *OH free radicals, the thiolate group (SH) of PDI
is converted into inactive S-nitrosylated (S-NO) and (S-OH) group78. Chronic exposure to these
harmful free redicals can jeopardize the posttranslational process of to be secreted proteins due to
reduced PDI functionality. Aggregation of proteins and ER stress have been linked to the snitrosylation of PDI58,77,78.

1.7 Ubiquitin protease system (UPS)
The importance of ubiquitin in tagging misfolded, denatured, unfolded, damaged or
improperly translated proteins was very recently realized. Ubiquitinated proteins are destined for
the proteosomal dedragation system. The whole cycle of events is known as Ubiquitin Protease
System (UPS).

Fig. 1.14. Schematic of Ubiquitin Proteosome System (UPS).
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Ubiquitin, a 76 amino acids long protein, needs ATP for activation. Ubiquitination of
targated protein starts with the help of three enzymes, i.e. E1, E2 and E3 (Fig. 1.13)58. Of the
previously mentioned enzymes, E1 activates the ubiquitin protein then, E2 prepare the ubiquitin
for attachment whereas E3 helps to recognize the proper substrate for ubiquitin to bind with52,55.
The ubiqutinated substrate is targeted for degradation by a proteosome, the major component of
UPS52,58. The 26S proteosome is composed of 20S (functional domain) and a 19S subunit
(regulatory domain). After degradation of tagged proteins, the proteosome recycles the ubiquitin
for its next use58.
The UPS system helps to maintain the amino acid pool by recycling the amino acid from
degraded proteins. Increased accumulation of ubiquitinated proteins is an indication of stress
response and that often leads to activation of the apoptotic pathway55. Abnormality in the UPS
system is often related with several pathologies like: autoimmune disease, cancer, diabetes,
stroke, AD, ALS, PD, multiple sclerosis etc.52,55.

1.8 Prion like propagation
Prion protein (PrPC) isoforms control various biological functions including, the immune
response, long-term memory storage, and translation termination79-81. PrPC is a glycosylphosphatidylinositol-anchored glycosylated protein attached to the outer leaflet of the cell
membrane. An abnormal isoform of prion protein (PrPSc) is the causative agent of a fatal
neurodegenerative disorder, known as prion disease, which affects both humans and animals81-83.
Importantly, PrPSc is infectious and transmits experimentally or naturally among the same
species or even across different species. Alternatively, folded PrP (PrPSc) acts as a template that
self-propagates by inducing the misfolding of normal prion protein (PrPC) into a structured PrPSc
polymer, ultimately leading to aggregation and neurodegeneration84.
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Fig. 1.15. Schematic representation of amyloid and prion formation.

Late onset characteristics of AD, despite the presence of the mutation from birth, gave
rise to speculation of prion like self-propagating Aβ protein aggregates throughout the brain80,81.
Several evidence argues that Aβ is a prion82,83. There is direct evidence for the existence of Aβ
prions, defined as Aβ assemblies capable of self-propagation within the brain84. Though it is not
clear what accounts for the different potencies of the brain-derived and synthetic beta-amyloid.
Failure of the ubiquitin-proteasome system that normally degrades misfolded proteins leads to
the formation of so-called aggresomes, pericentriolar inclusions85,86. These proteinaceous
aggregates can induce cytosolic assembly of aggregation-prone soluble proteins through a
seeding-like mechanism that shares similarities with prion propagation87-90. It is also speculated
that Aβ (1-42) fragment can also induce the aggregation in other amyloidogenic proteins (Fig.
1.15).
In the case of functional prion protein, the secondary structure is α-helix dominated
whereas the abnormal PrPSC is β-sheet dominated (Fig. 1.16). The same trend can be noticed in
amyloidogenic proteins like α-synuclein, amyloid beta etc80. All these features gave rise to the
speculation of prion-like propagation of amyloidogenic proteins91.
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Fig. 1.16. Probable mechanisms behind β-amyloid and α-synuclein cross reactivity. Several
postulated mechanisms by which α-synuclein (α-syn) and β-amyloid (Aβ) may interact to form
Lewy body. Such mechanisms include (left to right): chronic inflammation and microglial
activation induced by both Aβ and α-syn; direct interactions and hybrid oligomerization of Aβ
and α-syn; Aβ-induced kinase activation and α-syn phosphorylation; impairment of proteasome
and autophagy degradation pathways; and Aβ-induced phosphorylation of tau leading to taumediated enhancement of α-syn aggregation. (CK-2, casein kinase 2; PLK-2, polo-like kinase 2;
PHF, paired helical fi laments; NFT, neurofi brillary tangle; p-Tau, phosphorylated tau; pS129,
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phosphorylated at serine 129; p-syn, phosphorylated α-synuclein; UPS, ubiquitin–proteasome
system). (Adapted from S.E. Marsh et. al. 2012)

Fig. 1.17. Change from α-helix dominated functional protein structure to non-functional β-sheet
dominated aggregated protein striking a common ground between AD, PD and Prion disese.

1.9 Polyphenolic compounds and intrinsic metabolites as potential drug therapies
Diphenyl difluoroketone (EF24)
The present investigation studied to determine the, Diphenyl difluoroketone, (EF24,
Fig.1.18.A) a curcumin analog, against the rotenone induced nitrosative stress. Curcumin is a
turmeric (Curcuma Longa) spice which has already been used clinically and is approved by the
FDA to scavenge excess ROS and protect PDI function under conditions of nitrosative stress.
However curcumin’s low bioavailability and efficacy profile in vivo hinders its clinical
development92. Currently, EF24 is being used as an anticancer drug and found that EF24 is more
efficacious and considerably a less toxic, commonly used chemotherapeutic agent93. In this
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study, I assessed the free radical scavenging property of EF24 to prevent the protein misfolding
leading towards apoptotic cell death.
Na-D-β-Hydroxybutyrate (NaβHB; C4H7NaO3)
NaβHB (Fig.1.18.B) is a ketone body produced by hepatocytes and serves as an
alternative source of energy in the brain during starvation94,95. Neuronal damage induced by
glucose deprivation and mitochondrial poisoning is prevented by NaβHB96,97. Ketone bodies
decrease the need for glycolysis98, bypass the blockade of the pyruvate dehydrogenase multienzyme complex, and reduce the mitochondrial [NAD+]/ [NADH] ratio (Fig. 1.17)99,100.

Fig. 1.18. Hypothesized effects of βHB on mitochondrial inhibition by rotenone.
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In this study, I have investigated the neuroprotective effect of NaβHB against rotenone
induced caspase-activated apoptosis by using SH-SY5Y dopaminergic neuroblastoma cells.
Furthermore, the aggregation of overexpressed green-fluorescent protein tagged synphilin-1 in
SH-SY5Y cells was monitored. This work can open avenues for the design and development of
more effective prophylactics against nitrosative-stress linked PD.
Piperine
Piperine (Fig.1.18.C; C17H19NO3), the alkaloid is found in P. nigrum L. and P. longum L is
traditionally used as an Indian spice101. Piperine, popularly known as black pepper is believed to
have the antidepressant effect and cognitive enhancing effect during entire treatment duration in
mice102. Most interestingly, piperine was found to have antioxidant and anti-apoptotic properties
and anti-apoptotic property103,104. Some research groups claimed to observe increased
bioavailability of different test drugs in blood vessels when administered along with piperine105108

.

Ellagic Acid
Ellagic acid (EA)- 2,3,7,8-tetrahydroxy-chromeno (Fig. 1.18.D; C14H6O8) a plant polyphenol,
present in fruits and berries such as pomegranates, strawberries, raspberries and blackberries,
exerts strong antioxidative, anticarcinogenic, and antifibrosis properties109-112. Antioxidants are
compounds that can delay, inhibit or prevent the oxidation of compounds by trapping free
radicals and reducing oxidative stress. In various commercial products, the presence of ellagic
acid as antioxidant has also been reported. These molecules can also act as inhibitors of human
immunodeficiency virus (HIV)113,114. The polyphenolic ring is suggestive of its antioxidant
property as well as, it can be predicted from the structure, it’s ability to scavenge reactive
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nitrogen specie. In this study, we want to investigate the efficacy of ellagic acid along with
previously mentioned small molecules.

Fig. 1.19. Schematic of polyphenolic compounds and intrinsic metabolites. (A) Curcumin
analogue EF24, (B) Sodium beta hydroxybutyrate, Polyphenolic phytochemicals Piperine (C)
and Ellagic acid (D).

1.10 Serum protein human serum albumin (HSA)
Albumin is a monomeric soluble protein highly abundant in blood serum. Human
serum albumin (HSA; Fig. 1.19) carries several endogenous compounds like steroids, thyroid
hormones, fatty acids and helps to maintain extracellular fluid balance115. Due to its ability to
depot various drug molecules, HSA has long been studied and is of interest to the pharmaceutical
industry115. Moreover, HSA has shown antioxidant property as well as it is a carrier of NO115.
The primary sequences indicate that there are three homologous domains (I, II and III), each
containing two sub-domains (A and B) which are stabilized by 17 disulfide bridges116.
Heterocyclic and aromatic ligands were found to bind within two hydrophobic pockets in subdomains IIA and IIIA, namely drug site 1 and drug site 2 (Fig. 1.19). A total of seven fatty acid
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binding sites were discovered in subdomains IB, IIIA, IIIB and on the subdomain interfaces116.
HSA also has a high affinity metal binding site at the N-terminal end117. Flexibility of the
multiple binding domains enhances the ability of HSA to interact with many organic and
inorganic molecules at different physiological conditions. The same drug molecule can also bind
to different locations with different affinity in HSA depending on the following competitive and
synergistic mechanism116. Allosteric conformation change depends on physiological pH, which
helps HSA to release the small molecules at diffent locations. Thsese properties make this
protein a natural choce for pharmacokinetic study117.
Therefore, we choose HSA as a carrier protein for our proposed small molecule to its site
of delivary. In our study, the binding affinity of small molecules with HAS been carried out in
aqueous solution at physiological conditions, using constant protein concentration.

Fig. 1.20. Diagram of human serum albumin (HSA), PDB: 1E7H
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1.12 Dissertation hypothesis

We hypothesize that reactive oxygen species/ reactive nitrogen species insult and the
associated catalytic dysfunction of protein disulfide isomerase via its chemical modification
results in the accumulation of PD and AD-specific aggregates, alpha-synuclein and Aβ,
respectively. As a corollary, we posit that select small-molecules are neuroprotective.

We also hypothesize that beta-amyloid (25-35) aggregosome can lead to aggregation of
synphillin-1 and α-synuclein, making it cross-reactive.
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1.13 Dissertation aim
Specific Aim 1: To investigate neuroprotective effects of the innate metabolite, NaβHB against
rotenone-mediated synphilin-1 aggregation in SH-SY5Y cell line.

Specific Aim 2: To determine the efficacy of select polyphenolic phytochemicals against
nitrosative stress-induced α-synuclein aggregation and/or aggravated interaction of synphillin-1
and α-synuclein in dopaminergic cells.
Specific Aim 3: To characterize the “prion like propagation” features of aggregated betaamyloid (25-35) on synphilin-1 and α-synuclein expressed by dopaminergic cells.

Fig. 1.21. Schematic of experiments followed to test proposed aims.
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CHAPTER 2
Nitrosative stress mediated misfolded protein aggregation mitigated by Na-Db-hydroxybutyrate intervention
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2.1 Introduction
Pathologically, Parkinson’s disease (PD) is characterized by the progressive loss of
dopaminergic neurons in the substantia nigra and the formation of Lewy-body inclusions1.
Although the molecular mechanisms are not clearly understood, mitochondrial dysfunction is
known to be an important factor among other known intra- and extracellular etiological factors1.
Studies showed that in a particular sporadic form of PD, mitochondrial complex I activities are
compromised in the nigro-striatal pathway2-4. Rotenone, a plant derived pesticide, induces cell
destruction by inhibiting complex I (NADH ubiquinone oxidoreductase) which mimic the
biochemical lesions of PD, both in vivo and in vitro5,6.
The mitochondrial respiratory chain is a key site of reactive oxygen species (ROS)
production under physiological conditions which in turn, orchestrates apoptosis4,7,8. Rotenone is
a model ROS generator via the induced production of NOx. Earlier studies have shown the
mechanism of rotenone-induced apoptosis through mitochondrial ROS production2. Apoptotic
stimuli instigate the release of cytochrome c from the mitochondria into the cytosol, where it
triggers autocatalytic processing of procaspase-9. Caspase-3 gets activated along with other
effector proteins by caspase-9, resulting in the proteolytic cleavage of substrate nuclear poly
(ADP-ribose) polymerase (PARP)9. In human PARP, the cleavage occurs between Asp214 and
GLY215, which separates the PARP amino-terminal DNA binding domain (24 kDa) from the
carboxy-terminal catalytic domain (89 kDa)5,10. Cleavage of PARP facilitates cellular
disassembly and serves as a marker of cells undergoing apoptosis11.
A hallmark event characteristic of PD is the accumulation of aggregated proteins to often
form Lewy-bodies in the cytosol of human neuronal cells, which results apoptotic cell death of
dopaminergic neuronal cells3. A common feature observed in the neuronal cells of PD victims in
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this sporadic variant was the attachment of nitric oxide (NO) to the redox-active cysteines of
protein disulfide isomerase (PDI) to form S-nitroso-PDI because of highlevels of nitrosative
stress3,12. The formation of S-nitroso-PDI coupled with the pathogenesis of PD making the
oxidoreductase a chief target for the prevention of PD in the nitrosative-stress-linked variant of
the diseases12.
Na-D-b-hydroxybutyrate (NabHB; C4H7NaO3) is a ketone body produced by hepatocytes
and serve as an alternative source of energy in the brain during starvation13,14. Neuronal damage
induced by glucose deprivation and mitochondrial poisoning is prevented by NabHB15,16. Ketone
bodies decrease the need for glycolysis17, bypass the blockade of the pyruvate dehydrogenase
multienzyme complex, and reduce the mitochondrial [NAD+]/ [NADH] ratio18,19.
In this study, we investigated the neuroprotective effect of NabHB against rotenone
induced caspase-activated apoptosis by using SH-SY5Y dopaminergic neuroblastoma cells. Our
results reveal that NabHB attenuate the apoptotic stimuli by acting against rotenone toxicity.
Furthermore, we have monitored the aggrega tion of overexpressed green-fluorescent protein
tagged synphilin-1 in SH-SY5Y cells. Our results show that exposure of this cell line to rotenone
leads to the aggregation of synphilin-1, as observed by fluorescence microscopy and consistent
with previous reports that NO influences Lewy-body formation via PDI modification12.
Importantly, cells that were pre-incubated with NabHB prior to rotenone insult demonstrated a
marked resilience to synphilin-1 aggregation. These results suggest that it may be possible to
mitigate nitrosative-stress induced aggregates in cell lines using ketone body-analogs. Our work
opens avenues for the design and development of more effective prophylactics against nitrosative
stress linked PD.
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2.2 Materials and methods
Reagents, cell line and plasmid
Sodium beta hydroxy butyrate (NabHB) and rotenone (RT) were purchased from Sigma–
Aldrich (St. Louis, MO). Other reagents were commercially sourced: mouse monoclonal for
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and PARP (Cell Signaling Technology,
Danvers, MA); apoptosis/necrosis kit (Beckman Coulter, Miami, FL), horseradish peroxidase
(HRP)-conjugated goat anti-mouse (KPL Biomedical); Hoechst 33342 (Invitrogen, Eugene, OR);
propidium iodide (PI) (MP Biomedicals, Solon, OH); human neuroblastoma cell line SH-SY5Y
(ATCC, Manassas, VA). Cells were transfected with the pEGFP-C2 or synphilin-1/pEGFP-C2
plasmid as previously described3.
Cell culture and treatment
SH-SY5Y cells were cultured in a 1:1 mixture of DMEM and Ham’s F12 medium
supplemented with 10% fetal bovine serum, 1% penicillin–streptomycin. Cells were grown at 37
ºC in humidified 5% carbon dioxide atmosphere. SH-SY5Y cells (1 X 106 cells/ well) were
seeded onto glass coverslips in 6-well plates and incu bated for 12 h. Cell transfections were
performed the following day with pEGFP-C2 control (without insert) or pEGFP-C2 carrying the
fusion protein GFP-synphilin-1, as recommended by manufacturer using Effectene reagent
(Qiagen, Valencia, CA). After transfection, the cells were incubated overnight to allow
expression of proteins. Cells were treated with vehicle (DMSO) or with 100 µMNabHB for 6 h
followed by exposure to 300 nM of rotenone for 12 h. After incubation, cells were prepared for
microscopy as described below.
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Differential nuclear staining cytotoxicity assay
Cells were grown for 24 h to allow attachment to multi-well plates. Cells were treated
with rotenone or with different concentrations (5–500 µM) of NabHB alone, to determine it’s
possible cytotoxic effect. As control for non-specific effects, DMSO vehiclecontrol, as contained
in the experimental samples, was included at final concentration of 0.2% v/v. Cells were
pretreated with100 µMof NabHB for 6 h prior to rotenone exposure. Subsequently, cells were
incubated by an extra 24 h and images were captured in live mode20. A mixture of PI and
Hoechst 33342 at a final concentration of 1 µg/ ml was added to each well 1 h prior to imaging20.
Images were acquired in a live-cell mode utilizing a BD Pathway 855 Bio imager system (BD
Biosciences Rockville, MD). Montages (3 X 3) from nine adjacent image fields were captured
per well utilizing a 20 X objective. Captured images and data analysis determining the
percentage of death cells from each individual well was performed by using BD AttoVision™
v1.6.2 software (BD Biosciences Rockville, MD). Data were assessed in quintuplicate.
Apoptosis/necrosis assay
SH-SY5Y cells were seeded on 24-well micro plate at density of 20,000 cells/ well and
cultured as described. Cells were incubated overnight followed by 6 h pre-incubation in presence
of 100 µM NabHB and then added with 300 nM rotenone and incubated for additional 24 h.
Cells from each individual well were collected, washed and processed essentially as described
previously21. Briefly, cells were concurrently stained by resuspending them in a solution
containing Annexin V-FITC and PI dissolved in 100 µl of binding buffer (Beckman Coulter,
Miami, FL). After incubation for 15 min on ice in the dark, ice-cold binding buffer (400 µl) was
added to the cell suspensions, gently homogenized, and immediately analyzed by flow
cytometry. The percentage of total apoptotic cells per sample is annotated as the sumof both
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early and late stages of apoptosis (Annexin V-FITC positive), bottom right quadrant and top
right quadrant, respectively. For each sample, approximately 10,000 individual events were
acquired using flow cytometer (Cytomics FC 500; Beckman Coulter,Miami, FL) and data
analyzed with CXP software (Beckman Coulter, Miami, FL). Every experimental point, as well
as all controls, was assessed in quintuplicate.
Western Blotting
Total cell lysates were prepared by washing the cells with cold Tris-buffered saline,
collected by centrifugation (3003g, 5 min at 4 ºC, and extracted by sonication in buffer
containing 10 mM Tris–HCl (pH 7.4), 10 mM EDTA, 0.5% (v/v) SDS and protease inhibitors
(Sigma). Total protein concentrations were measured using a bicinchonic acid kit (Pierce,
Rockford, IL) and BSA as standard. Equal amounts of protein (approximately 10 µg per lane)
were separated using SDS–polyacrylamide gel electrophoresis and then transferred to
polyvinyldifluoride (PVDF) membranes. Blots were incubated in blocking buffer (5%, w/v, dried
skimmed milk in Tris–buffered saline, pH 7.4, and 0.1% Tween 20) followed by incubation with
anti-PARP rabbit polyclonal antibody (1:1000) or anti-GAPDH (1:1000 dilution) diluted in
blocking buffer for 1 h followed by horseradish peroxidase (HRP)-conjugated goat anti-rabbit in
1% BSA/TBST for 30 min. Chemiluminescence (ECL-plus or SuperSignal West Pico
Chemiluminescent Substrate) was used according to the manufacturer’s instructions (Amersham
or Pierce Biotechnology Inc.). GAPDH was used as housekeeping protein loading control.
Transfection and cell treatment
SH-SY5Y cells (1 X 106 cells/well) were seeded onto glass coverslips in 6-well plates
and incubated at 37 ºC in 5% CO2 for 12 h. Cell transfections were performed in the following
day as recommended by manufacturer using Effectene reagent. Cells were then incubated with
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transfection complexes under normal growth condition for expression of pEGFP-C2 control or
the fusion protein GFP-synphilin-1 gene. Transiently transfected SH-SY5Y cells were incubated
overnight to allow expression of proteins. Cells were treated with DMSO vehicle or with 100
µM NabHB for 6 h followed by exposure to 300 nM of the toxicant rotenone for 12 h. After
attachment, cells were prepared for microscopy as described below.
Confocal microscopy and immunocytochemistry
Cells transfected with vector or EGFP-synphilin-1 were washed after treatment, fixed
with 4% paraformaldehyde in PBS, stained with DAPI and mounted under ProLong antifade
medium (Molecu lar Probes). To stain for synphilin-1, cells were fixed as above, permeabilized
with 0.1% (w/v) saponin in PBS, blocked with PBS plus 5% goat serum, 5% FBS and 0.1%
TWEEN 20, followed by incubation with primary antibody (overnight at 4 ºC) and secondary
rhoda mine-conjugated goat anti-mouse (1:10,000; KPL Biomedical), and DAPI staining.
Fluorescence confocal images were captured utilizing LSM 700 confocal microscope and
assisted with ZEN 2009 software (Zeiss, New York, NY).
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2.3 Results
Differential nuclear staining assay to quantify cytotoxicity
Results from the cells differential nuclear staining assay (DNS) are shown in Fig. 2.1. To
define and analyze survival and death of SH-SY5Y, dead cells were detected by using PI (Fig.
2.1B); and, entire, nucleated cells were stained with membrane permeable Hoechst dye (Fig.
2.1A). Colocalization (magenta color) of nuclear fluorescence signals as shown in Fig. 2.1C
represents the dead cells. The DNS assay adapted to HTS revealed cytotoxicity of NabHB itself
and preventive effect of NabHB against rotenone induced cytotoxicity in SH-SY5Y cell. Fig.
2.1D shows the dose response assay of NabHB in SH-SY5Y cell line. Our data reveals no
significant cytotoxicity up to 500 µM NabHB.
The cytotoxicity by rotenone insult was measured in the presence and absence of NabHB. Preincubation with 100 µM NabHB lowered the level of 300 nM rotenone cytotoxicity (Fig. 2.1E).
Our results illustrated in Fig. 2.1D showed no significant differences between control after
DMSO treatment and 100 µM NabHB treatments for 24 h. We found more than 70% toxicity at
300 nM rotenone on SH-SY5Y cells after 24 h of incubation (Fig. 2.1E). It is clear in Fig. 2.1E
that pre-treatment with 100 µM NabHB (6 h) followed by rotenone insult for 24 h resulted in
reduction of cytotoxicity to a significant level (~25%). Based on these results it is obvious that,
NabHB, classified as a ketone body, can prevent the mitochondrial inhibitor rotenone mediated
cell death.
Apoptosis/necrosis assay
Fig. 2.2 depicts annexin V-FITC and propidium iodide (PI) flow cytometric analysis to
quantitatively estimate the apoptotic/ necrotic profiling of SH-SY5Y cells upon different
treatment. Each histogram in Fig. 2.2 is fragmented in four quadrants; left top quadrant –
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necrosis, cells permeable to PI that have lost theirmembrane integrity, without Annexin V-FITC
signal, one color (red); right top quadrant – late apoptosis, cells with compromised plasma
membrane, permeable to PI, but also with Annexin V-FITC signal, two colors (green and red);
lower left quadrant – alive unstained cells, without PI or Annexin V-FITC fluorescent signal;
lower right quadrant-early apoptosis, cells with only Annexin V-FITC signal, one color (green).
Representative histograms of untreated cells (Fig. 2.2A); cells treated with DMSO (Fig. 2.2B)
and 100 µM NabHB (Fig. 2.2D), did not show much detrimental effect on the viability of SHSY5Y cells. Approximately, 2% of cells survive the exposure of 150 µM H2O2 (positive control)
as shown in Fig. 2.2C. Apoptotic cell death occurred of nearly 70% (early and late apoptosis
combined) after 24 h exposure to 300 nM rotenone (RT) in SH-SY5Y cells (Fig. 2.2E).
Pretreatment with 100 µM NabHB for 6 h resulted in ~40% and ~10% protection against
rotenone (300 nM) induced late and early apoptotic cell death respectively (Fig. 2.2F) and almost
preserves the characteristic as of control.
Total percentage of apoptotic cells were expressed as the sum of both early and late
stages of apoptosis (light colored bars; Fig. 2.2G). Cells permeable to propidium iodide without
Annexin V-FITC signal were considered as necrotic cells (dark colored bars; Fig. 2.2G).
Untreated cell (Con.), vehicle control (DMSO) as well as 100 µM NabHB treated cells showing
negligible apoptotic and necrotic cell death (Fig. 2.2G) as anticipated from previous data (Fig.
2.1D and E).
Rotenone induced excessive generation of NOx resulted in cell death mostly via apoptotic
pathway. Interestingly, rotenone even outcast 150 µM H2O2 induced apoptotic cell death by
10%. Necrotic cell death due to rotenone aggression was very low over control. Our data clearly
suggest that rotenone, a known NOx producer, can activate the caspase pathway through
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mitochondrial membrane depolarization leading towards apoptotic cell death. Fig. 2.2 also
revealed that cells pre-incubated with 100 µM NabHB for 6 h can clearly prevent rotenone
induced apoptosis by ~40% in SH-SY5Y.
PARP assay
In Fig. 2.3, lane 1, 2, 3, 4 and 5 (Ln = 1–5) indicates untreated cells, vehicle control
(DMSO), cells treated with sodium beta hydroxy butyrate (NabHB; 100 µM), cells pretreated
with NabHB (100 µM) for 6 h and exposed to 300 nM of rotenone for another 24 h and cells
treated with rotenone (300 nM) alone respectively. Our data show that stress with 300 nM
rotenone on cells for 24 h increases cleavage of PARP at a very high level over control (Fig.
2.3). Excess generation of NOx, upon rotenone insult, facilitates cleavage of the PARP carboxyterminal catalytic domain (89 kDa) from amino-terminal DNA binding domain (24 kDa) (Fig.
2.3, Ln5), which activates the apoptotic pathway. In this experiment we show that 100 µM
NabHB can prevent the cleavage of PARP (Fig. 2.3, Ln4), suggesting the generation of low
nitrosative stress and thus protecting the SH-SY5Y cells from going through apoptosis.
S-Nitrosylation of PDI mediates synphilin-1 aggregation in model cells of PD
Fig. 2.4 shows the protective effect of NabHB on aggregation of GFP-tagged synphilin-1
by confocal microscopy in transiently transfected SH-SY5Y cells as a function of rotenone
insult. The results clearly indicate the aggregation of synphilin-1 when exposed to 300 nM
rotenone (Fig. 2.4D). Pre-treatment of cells with 100 µM NabHB prior to 300 nM rotenone
exposure shows markedly diminished level of synphilin-1 aggregation (as evidenced through
GFP fluorescence; Fig. 2.4E). Fig. 2.4A revealed a relatively homogeneous cytosolic distribution
of GFP in cells transfected with pEGFP C2 plasmid alone. In contrast, cells transfected with
EGFP- synphilin-1 constructs show a punctuated (or speckled) cytosolic distribution of green
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fluorescent signal (Fig. 2.4B). This observation indicates that over expression of synphilin-1
fused to EGFP protein does not display homogenous cytosolic distribution, instead, accu
mulating subcellularly in the form of aggresomes. Cells, treated with the vehicle alone (DMSO;
Fig. 2.4C) or 100 µM NabHB (Fig. 2.4F) did not differ in the expression of EGFP-synphilin-1 as
compared to untreated cells (Fig. 2.4B).
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2.4 Discussion
In eukaryotes the mitochondrial respiratory chain (complexes I–V) is the major site of
ATP production; additionally, it significantly impacts apoptosis. Inhibition of the mitochondrial
respiratory chain by rotenone is linked to ROS production and serves to study the role of the
mitochondrial respiratory chain in apoptosis22. NOx-stress, an outcome of ROS elevation, results
in caspase-9 and caspase-3 activation, PARP cleavage, and DNA fragmentation eventually
leading to apoptotic cell death.
The endoplasmic reticulum is a specialized compartment with a redox potential designed
to facilitate the (oxidative) formation of disulfide bonds in secretory or membrane-bound
proteins3. This is an essential process preceding their export from the ER and is catalyzed by
protein-disulfide isomerase, the chief ER-resident oxidoreductase chaperone. The catalytic
function of PDI, executed through two redox-active cysteine-containing active sites is essential
to balance the flux between incoming nascent polypeptides and outgoing biologically viable
folded proteins3. Compromise or failure in the catalytic efficiency of PDI can reduce the
maturation processing of nascent substrates and lead to terminal misfolding, retrotranslocation
along the endoplasmic reticulum associated degradation (ERAD) pathway and debris
accumulation in the cytosol. This sequence of events is perhaps the rosetta-stone for the onset of
apoptotic cell death related neuropathies3.
Here, we hypothesized that the NabHB can mitigate the incidence of apoptotic cell death
propagated by nitrosative stress.
To test our hypothesis, we employed rotenone to initiate nitrosative stress in an SHSY5Y cell line. We first determined the cytotoxicity of rotenone and prophylactic effect of
NabHB against rotenone through differential nuclear staining cytotoxicity assay.
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Although we were unable to detect the mechanism of cell death (apoptotic or necrotic) by
this assay, out study demonstrated that rotenone induced cytotoxicity was reduced to a
significant level in the presence of NabHB.
Next, we determined the mechanism by which rotenone induces nitrosative-stress-related
cell death (i.e. via the apoptotic and/or necrotic pathway).We used flow cytometric assay to
determine the pathway of rotenone induced cytotoxicity in SH-SY5Y cell line; additionally, we
examined the preventive effect of NabHB against rotenone-induced nitrosative-stress-related
apoptotic or necrotic cell death. Our data indicate that rotenone causes cytotoxicity in SH-SY5Y
cell line primarily through the apoptotic pathway and NabHB mitigates apoptotic cell death at a
very significant level by attenuating nitrosative stress.
PARP analysis also confirmed that rotenone-induced nitrosative stress leads to cell death
essentially through apoptosis. Excessive generation of NOx by mitochondrial complex-I
inhibitor rotenone leads PARP cleavage via caspase activity and that activates apoptotic stimuli
in eukaryotic cell. We determined that rotenone induced PARP cleavage is significantly reduced
in the presence of NabHB. This reinforces evidence for prophylactic ability of NabHB against
apoptotic cell death.
Collectively, our data reveal that rotenone-induced nitrosative stress activates
programmed cell death stimuli and leads to apoptotic cell death via caspase-9 and caspase-3
activation. NabHB prophylactic effect against nitrosative-stress-related apoptotic cell death
might arise from its inhibitory behavior towards one or more elements within this cascade.
Initially, we examined the cytosolic aggregation of synphilin-1 in the SH-SY5Y cell line
under rotenone-induced nitrosative stress as previously demonstrated12. GFP-labeled synphilin
aggregation was monitored using confocal microscopy. In comparison to control experiments,
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incubation of the cell line with rotenone clearly demonstrated cytosolic aggregation of synphilin1 consistent with previous results suggesting that healthy PDI inhibits aggregation of synphilin1. In other controls, we examined whether unstressed cells expressing PDI could prevent
synphilin-1 Lewy-body-like inclusions in the cytosol after synphilin-1 overexpression. Our data
revealed very limited diffused synphilin-1 localization in cytosol (Fig. 2.4B and C). In contrast,
rotenone treated cells showed discrete inclusions of synphilin-1 in the cytosol.
These results suggest that rotenone-dependent elevation of nitric oxide attenuated the
protective effect of PDI on synphilin-1 inclusions (Fig. 2.4D). Next, cells were preincubated with
NabHB prior to rotenone exposure to determine whether NabHB can prevent rotenone induced
aggregation formation of misfolded protein. Confocal microscopy data monitoring GFP-tagged
synphilin-1 clearly indicate that unlike rotenone-induced nitrosative stressed cells Fig. 2.4D),
cells pre-treated with NabHB followed by rotenone treatment showed a drastic decrease in
discrete Lewy-like inclusions in cytosol (Fig. 2.4E). These results suggest that NabHB can
intracellularly rescue S-nitroso modification of PDI as seen under elevated levels of nitrosative
stress and prevent Lewy-neurite formation in our model system.
In conclusion, our data reveals that the innate metabolite NabHB can serve as a potent
prophylactic against nitrosative stress induced pathogenesis of PD. It remains to be investigated
whether NabHB can intervene in other reactive oxygen species initiated sporadic neuropathies
such as Alzheimer’s disease.
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Fig. 2.1. The cytotoxicity and preventive effect of NaβHB was tested utilizing SH-SY5Y cell
line, measured by using differential nuclear staining assay (DNS) adapted to high throughput
screening (HTS). (A) Hoechst emission signal indicates the total number of nuclei (cells), shown
in blue. (B) Propidium iodide emission signal indicates the number of death cell, shown in red.
(C) Magenta color is an outcome of co-localization of red (PI) and blue (Hoechst) colors
indicating the number of death cells in the image. (D) The cytotoxicity of NaβHB at different
concentration after 24 h of treatment and (E) Preventive effect of NaβHB against rotenone
toxicity in SH-SY5Y cells. Each bar represents average of triplicate values, and error bars their
corresponding standard deviation.
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Fig. 2.2. Representative flow cytometric dot plots used to determine the percentages of
apoptosis/necrosis effects on SH-SY5Y cells. (A) untreated cells (control), (B) vehicle control
(dimethyl sulfoxide; DMSO), (C) positive control (150 µM H2O2), (D) cells treated with sodium
beta hydroxy butyrate (NabHB; 100 µM), (E) cells treated with rotenone (300 nM), (F) Cells
were pretreated with NabHB (100 µM) for 6 h and exposed to 300 nM of rotenone for another 24
h. (G) represent the percentage of apoptotic and necrotic cell population.
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Fig. 2.3. Protective effect of NaβHB (100µM) against rotenone (300nM) induced poly (ADPribose) polymerase (PARP) cleavage, marker of apoptosis progression, in SH-SY5Y cells.
PARP cleavage was analyzed via Western blot analysis.
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Fig. 2.4. Expression of synphilin-1 in SH-SY5Y cells and rotenone induced aggregation. (A)
cells transfected with pEGFP-C2 without synphilin-1 insert; (B) cells untreated; (C) cells treated
with DMSO 0.2% v/v; (D) cells exposed to 300 nM rotenone for 12 h; (E) cells pretreated with
100 µM NaβHB for 6 h were exposed to 300 nM rotenone for 12 h; (F) cells exposed to 100 µM
NaβHB. All the cells were counterstained with DAPI to delimitate the nucleus (blue color).
White arrows indicate the presence of aggregates corresponding to the recombinant fusion
protein and yellow arrow represents GFP expression. Second part of each figure represents the
differential interference contrast (DIC) picture merged with fluorescence images.
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CHAPTER 3
SNO-PDI mediated accumulation of Parkinsonian biomarkers in PC12 cell
death: ellagic acid interference
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3.1 Introduction
With no cure in sight and care burdens constantly rising and currently estimated at $23 and
$216 billion, respectively, Parkinson’s and Alzheimer’s diseases are emerging as a leading cause
of morbidity and mortality in the US1,2. Furthermore, recent studies revealed that Hispanics and
other minorities are especially prone to neuropathies due to a variety of geo-socio-economic
factors including exposure to pesticides in farms and fields and associated reactive oxygen
species (ROS) and reactive nitrogen species (RNS) insult3,4.
The housekeeping chaperone Protein Disulfide Isomerase (PDI) is normally responsible for
maturation of proteins and thus regulates traffic flow in the cell5,6. However, in post-mortem
brains of Parkinson’s and Alzheimer’s Disease victims, PDI has been found to undergo Snitrosylation of its catalytic cysteines in response to nitrosative stress7-11.
In follow-up cell line studies, the chemical modification of PDI promoted the aggregation
and accumulation of the minor, but signature, Parkinsonian-specific biomarker synphilin-1 in a
nitric oxide (NO)-sensitive manner9-11. However, overexpression of wild-type PDI (non-SNOPDI) attenuated the accumulation of synphilin-1-containing aggregates in the SHSY-5Y cell
line10.
In contrast to these studies involving synphilin-1, a gap exists in studies examining the
aggregation of other neurodegeneration-specific biomarkers in response to SNO-PDI
formation12,13. Specifically, no studies have examined the impact of SNO-PDI formation on the
aggregation of α-synuclein, the major Parkinsonian biomarker and principal Lewy body
constituent14-17. Here, we examined whether SNO-PDI formation provokes α-synuclein
aggregation and Lewy-like neurite formation, and thus, causes the nitrosative stress-associated
Parkinson’s pathogenesis.
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Also noteworthy, is the prominent gap in efforts designed to prevent nitrosative damage to
PDI. This is despite the fact that over seven years have passed since the discovery of the proven
association of this chemical mutation with synphilin-1 aggregation10. Lately, the housekeeping
chaperone Protein Disulfide Isomerase (PDI) has emerged as a critical neuroprotectant whose
catalytic integrity is pivotal to neuronal function18-21. Our objective was to test compounds that
can prevent SNO-PDI formation and can thus mitigate the accumulation of misfolded protein
debris such as Parkinsonian synphilin-1 and perhaps α-synuclein. Importantly, this research may
fill the void in molecular-level efforts toward preventing PD, the Lewy Body Variant of
Alzheimer’s Disease (LBVAD) and other neurodegenerative disorders given that a number of
other studies have confirmed that the functional security of cellular housekeeping machinery is
pivotal to neuronal health21-23.
Ellagic acid (EA), 2,3,7,8-tetrahydroxy-chromeno (C14H6O8), a plant polyphenol present in
fruits such as pomegranates, strawberries, raspberries, blackberries, etc. exerts strong
antioxidative, anticarcinogenic, and antifibrosis properties24,25. Growing interest on natural
products as effective prophylactic in many fields, instigated our work on EA as a potential
candidate for this study. In addition, we investigated the ability of EA to bind HSA with the
objective of improving its systemic distribution. HSA is a prominent carrier protein in the
circulatory system26,27; thus, having the ability to strongly interact with HSA plays an important
role in the transport and delivery of molecules such as EA.
Our results indicate that a rotenone-insult induced increase in ROS and RNS levels in the cell
is associated with SNO-PDI formation as well as that SNO-PDI formation triggers the
accumulation of the major PD biomarker α-synuclein. Our data also reveal that SNO-PDI
formation provokes co-localization and the concomitant formation of α-synuclein:synphilin-148

containing Lewy body-like aggregates, suggesting that SNO-PDI formation is a key milestone in
the pathogenesis of nitrosative stress-induced PD.

In addition, we demonstrate that EA

intervenes in nitrosative stress-associated endoplasmic reticulum (ER) stress, accumulation of
ubiquitinated proteins, apoptosis and the formation of lewy-like aggregates. Furthermore,
administration of Ellagic acid to the cell line prior to rotenone insult mitigated SNO-PDI
formation and the formation of synphilin-1, α-synuclein, and α-synuclein:synphilin-1-containing
Lewy body-like aggregates. Finally, the demonstrated ability of EA to reversibly bind HSA
makes it a viable choice to use as a prophylactic in ROS/RNS-induced neuropathies.
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2.2 Methods
Reagents, cell line and plasmid
Ellagic acid, Rotenone (RT), 2’, 7’-dichlorodihydrofluorescein diacetate (DCFH-DA),
Tetranitromethane and 4-amino-5-methylamino- 2'',7''-difluorofluorescein diacetate (DAF-FM
DA) were purchased for the study (Sigma–Aldrich; E2250, R8875, D6883, T25003 and Life
Technologies; D-23842 respectively). Other commercially sourced reagents were: Mouse
monoclonal for GAPDH antibody (Glyceraldehyde 3-phosphate dehydrogenase), poly(ADPribose) polymerase antibody, Ubiquitin antibody (Cell Signaling Technology; 3683, 46D11,
3933 respectively), protein disulfide isomerase antibody (Abcam; ab2792), HSP70 antibody
(SantaCruzBio; sc-66048), Hoechst 33342 (Life Technologies; H1399), propidium iodide (PI)
(MP Biomedicals, 195458), annexin V kit (Beckman Coulter; IM3546), horseradish peroxidase
(HRP)-conjugated goat anti-mouse and anti-rabbit antibody (KPL Biomedical; 214-1806 and
214-1516); rat pheochromocytoma derived neuronal PC12 cell (ATCC® Number: CRL-1721
™) from a male origin. Cells were transfected with the pEGFP-C2 or synphilin-1/pEGFP-C2 and
pCMV6 or α-synuclein/pCMV6 plasmid (NCBI Reference Sequence: NM_001146054.1) as
described46. Serum albumin from human ≥ 99% fatty acid free was obtained from Sigma-Aldrich
(A9511), DM45 spectrofluorimeter was obtained from Olis on-line instruments systems, INC
(Bogart, GA).
Mass spectrometry assay
Ellagic acid stock solution was prepared in acetonitrile then diluted to obtain
concentrations ranging from 0.1-80 µM (in acetonitrile). TNM was added from a stock solution
(freshly prepared by weight in acetonitrile) to EA at different ratios. The samples were analyzed
on a Q-TOF ESI negative mode mass spectrometer.
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Cell culture and Transfection
PC12 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were
routinely grown at 37°C in humidified 5% carbon dioxide atmosphere on complete DMEM
media. Trypsin-EDTA 0.25% (1X) (Life Technologies, 25200-056) was used to detach the cells
from the culture surface when needed and once detached, complete DMEM media was added to
the cell suspension. Subsequently, the cell suspension was centrifuged at 900 R.P.M. for 5
minutes in order to remove trypsin from incubation media. Cell transfections were performed the
following day after plating. Subsequently, cell transfections were performed with pEGFP-C2
control (without insert) or pEGFP-C2 carrying the fusion protein GFP-synphilin-1 and pCMV6
control or pCMV6 inserted with α-synuclein as recommended by manufacturer using
Lipofectamine® LTX with Plus reagent (Life technologies; 15338500). Transfected cells were
incubated overnight to allow expression of transfection complexes under normal growth
condition for expression of pEGFP-C2/pCMV6 (control) or the complex pEGFP-C2 with
synphilin1/pCMV6 with α-synuclein gene and both at the same time at a ratio of 1:1. Transiently
transfected PC12 cells were incubated overnight to allow expression of proteins.
Differential nuclear staining cytotoxicity assay
Cells were seeded into 96 multi-well plates and incubated for 24 h to allow attachment.
Subsequently, cells were treated with different concentrations of RT or EA to determine its
possible cytotoxic effects. As control for non-specific effects, DMSO vehicle control, as
contained in the experimental samples, was included at final concentration of 0.5% v/v. In
addition, in order to measure the ability of RA to intervene and protect against rotenone insult,
cells were pre-treated with 10 µM of EA for 6 h prior to rotenone exposure. Subsequently, cells
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were incubated for an additional 24 h and images were captured in live mode. A mixture of PI
and Hoechst 33342 at a final concentration of 1 μg/ml was added to each well 1 h prior to
imaging46. Images were acquired in a live-cell mode utilizing a BD Pathway 855 Bioimager
system (BD Biosciences Rockville, MD). Montages (3X3) from nine adjacent image fields were
captured per well utilizing a 10X objective. Image capture and data analysis determining the
percentage of cell death per each individual well was achieved by using BD AttoVision™ v1.6.2
software46 (BD Biosciences Rockville, MD). Each experimental point was assessed in
quintuplicate.
Detection of intracellular ROS and RNS
Intracellular ROS and RNS level was measured using the oxidation-sensitive fluorescent
probe DCFH-DA and DAF-FM DA respectively. Cells were seeded (5000/well) on 96-well plate
and treated with 10 µM DCFH-DA or 5 µM DAF-FM in 50 µL of DMEM media according to
manufacturer’s protocol. After treatment, cells were analyzed with a microplate reader
fluorometer (Labsystems Fluoroskan Ascent) using excitation at 485 nm and emission at 518 nm.
Each data point was assessed in quintuplicate. Images were captured using Carl Zeiss LSM 700
microscope, 20X lens.
Apoptosis/Necrosis assay using Fluorescence-Activated Cell Sorting
Cells were seeded on a 24-well micro plate at density of 20,000 cells/ well and cultured
as previously described. Cells were incubated for 6 h in presence of EA and then treated with RT
and incubated for additional 24 h. Cells from each individual well were washed, collected and
processed essentially as previously described46. Briefly, cells were concurrently stained by resuspending them in a solution containing Annexin V-FITC and PI dissolved in 100 μL of
binding buffer. After incubation for 15 min on ice and in the dark, ice-cold binding buffer (400
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μL) was added to the cell suspensions. The mixture was gently homogenized and immediately
analyzed by flow cytometry. The percentage of total apoptotic cells per sample is annotated as
the sum of both early and late stages of apoptosis (Annexin V-FITC positive), bottom right
quadrant and top right quadrant, respectively46. For each sample, approximately 10,000
individual events were acquired using flow cytometer (Cytomics FC 500; Beckman Coulter) and
data analyzed with CXP software (Beckman Coulter). Each data point was assessed in
quintuplicate.
Western blot analysis
Total soluble cell lysates were prepared by washing the cells with cold Tris-buffered
saline, collected by centrifugation (3003 xg, 5 min at 4°C, and extracted by sonication in buffer
containing 10 mM Tris–HCl (pH 7.4), 10 mM EDTA, 0.5% (w/v) SDS, protease and
phosphatase inhibitors (Thermo Fisher Scientific; 78442). The insoluble cell pellet was boiled
for 30 seconds after dissolving in 3X sample buffer (without beta marcaptoethanol) and
centrifuged for 1 min before loading to SDS-polyacrylamide gel electrophoresis46 (SDS-PAGE).
We used insoluble protein fraction to detect accumulation of ubiquitinated proteins. On the other
hand, after quantification, equal amount of soluble cell lysates (approximately 20 µg per lane)
were separated using SDS-PAGE and then transferred to polyvinyldifluoride (PVDF)
membranes. Blots were incubated in 5%, w/v, dried skimmed milk/ Tris-buffered saline pH 7.4,
and 0.1% Tween 20 (TBST) followed by incubation for 2 h with anti-PARP/ anti-α-synuclein/
anti-PDI/ anti-HSP70/ anti-ubiquitin monoclonal antibodies (1:1000) or anti-GAPDH (Loading
control; 1:1000) diluted in 3% BSA/TBST. After washes, blots were exposed to secondary
antibodies by incubating 1 h with horseradish peroxidase (HRP)-conjugated goat anti-rabbit in
5% dry skimmed milk/TBST for 30 min. Chemiluminescence (SuperSignal West Pico
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Chemiluminescent Substrate; Thermo Fisher Scientific; 34077) was used according to the
manufacturer’s instructions. Each data point was assessed in triplicate.
Co-immunoprecipitation and Tandem Mass Tag (TMT)-switch assay
Cell lysate was prepared following same procedure as western blot. To prepare positive
and negative control, cells were incubated for 30 minutes at room temperature with 200 µM Snitrosoglutathione or DTT, respectively. Proteins were separated in 10% SDS-PAGE, blotted and
visualized with specific antibodies. For detection of S-nitrosylated PDI, 200 µl lysates (1 mg/ml)
of PC12 cell homogenates were pre-cleared by the addition of 50 µL protein G agarose47 (Santa
Cruz Biotechnology). Next, 2.5 µg polyclonal anti-S-nitrosocysteine antibody (Abcam; ab50185)
or normal rabbit IgG (SantaCruzBio; sc-2027) was added to the supernatant, and the mixture
incubated for 1 h at 4°C with agitation. Immuno-complexes were precipitated by the addition of
50 µL protein G agarose, followed by incubation for 1 h at 4°C with agitation, and centrifugation
at 5000 R.P.M. for 2 min. The pellets were then washed thrice with 1 mL chilled TBS containing
1% (v/v) tween-20 and 1 mg/ml BSA and once with 0.5 M Tris–HCl. Following the final
centrifugation step, the pellet was re-suspended in SDS sample buffer, subjected to western blot
analysis, and immunostained for PDI as described previously.

We also used Pierce S-

Nitrosylation Western Blot Kit (Thermo Fisher Scientific; 90105) to detect S-nitrosylated protein
modification. This assay was performed following manufacturer instructions. In short, we used
anti-TMT antibody to pull down the cell lysate then detected using anti-PDI antibody. Each data
point was assessed in triplicate.
Confocal microscopy and immunocytochemistry
Cells transfected with empty vector or with EGFP-synphilin-1/ α-synuclein insert were
washed after treatment, fixed with 4% paraformaldehyde in PBS, stained with DAPI and
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mounted under ProLong antifade medium (Molecular Probes). To stain for synphilin-1/ αsynuclein proteins, cells were fixed as above, permeabilized with 0.1% (w/v) saponin in PBS,
blocked with PBS plus 5% goat serum, 5% FBS and 0.1% TWEEN 20, followed by incubation
with primary antibody (overnight at 4ºC) and secondary rhodamine-conjugated goat anti-mouse46
(1:10000; KPL Biomedical). Fluorescence confocal images were captured utilizing LSM 700
confocal microscope and assisted with ZEN 2009 software (Zeiss, New York, NY).
Immuno-blot, immuno-fluorescence and inclusion body quantification
To quantify protein expression and fluorescence intensity we used the open source
software Image J. Each logical storage manager (LSM) format data were opened in Image J and
converted into RGB file (8 bit). In order to quantify the fluorescence of expressed proteins,
random fields for each tested condition were obtained at the same magnification (63X oil
immersion objective, zoom 1.5X). Then, a region of interest (ROI) with an area of 400 pixels
(20X20) was chosen and the average intensity of fluorescence within the ROI was measured in
the cytosol of every transfected cell present in the field. Over 200 cells were analyzed for each
condition. The values obtained were averaged and were plotted using a bar graph. The results
were obtained from more than or equal to three independent experiments. Co-localization of two
different fluorescently labeled proteins was determined using ZEN 2009 software46 (Zeiss;
Supplementary Fig. 3). To count the cells with inclusion body we used colocalization finder in
Image J software. Randomly selected 5 different fields with more than 200 cells/field were
counted in three different sets of experiments to avoid the prejudice (Supplementary Fig. 4).
Protein binding assay
EA from a stock solution of 2.4 mM was aliquotted in a solution of 20 µM serum
albumin from human (HSA) (pH 7.5, 20 mM Tris-HCl). Fluorescence emission spectra were
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obtained 5 minutes after every titration by scanning the emission from 310 to 340 nm (Ext. 280
nm; DM45 sptecroflurimeter, Olis Instruments, GA). The quenching of fluorescence was fitted
to a binding curve43-45.
Statistical calculation
Every data point was collected independently and in triplicate. To note experimental
viability and variability, data were presented as the average with its corresponding standard
deviation. Statistical analysis was performed using two-tailed paired Student's t-tests to denote
the statistical significance of variances between experimental samples and their corresponding
controls. To identify if there is a significant difference between two groups, a value of P< 0.05
was considered significant. We denote the actual P-value in each graph wherever needed.

56

3.3 Results and discussion
Nitrosative stress-induced chemical mutation of a key housekeeping chaperone, protein
disulfide isomerase (PDI), has been convincingly implicated in the pathogenesis of sporadic
Parkinson’s and Alzheimer’s diseases7-11. While SNO-PDI formation triggers the aggregation of
the minor Parkinsonian biomarker synphilin-110, heretofore it remained unknown whether Snitrosylation-induced loss of catalytic function of PDI provoked the accumulation of the key
Parkinsonian protein α-synuclein. Using a variety of biochemical and analytical techniques we
investigated the relationship between SNO-PDI formation and the aggregation of α-synuclein
and α-synuclein:synphilin-1 containing (Lewy body-like) composites.

Furthermore, while

previous studies have demonstrated that overexpression of wild-type PDI attenuates the
accumulation of synphilin-110, it remains an unfeasible mechanism for therapeutic intervention.
In contrast, small molecules such as EA may provide therapeutically desirable alternatives for
prevention of neurodegeneration. We have assessed the ability of the small molecule
polyphenolic phytochemical ellagic acid to protect PDI from becoming S-nitrosylated. We have
also analyzed its efficacy in mitigating SNO-PDI associated aggregation of synphilin-1, αsynuclein and synphilin-1:α-synuclein composites (Lewy body-like neurites) and its ability to
bind to a carrier protein.
Cytotoxicity of EA and its free radical scavenging potential
Ability of EA as a potential free radical scavenger was determined by mass spectrometric
analysis, carried out in a controlled environment (Fig. 3.1A, B). A molecular weight of 301.232
Da in the negative ion mode suggests double deprotonation of EA28. In addition, a peak at
602.469 Da was observed which suggests the presence of EA dimers. Nitric oxide reacts with
29
cellular superoxide (O−
2 ) to form the peroxynitrite (ONOO ) resulting in ring nitration . We
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have employed tetranitromethane (TNM), a model mimic of peroxynitrite, as a NOx donor to
examine the ability of EA to scavenge RNS 30-32. Upon exposure of EA to TNM, a mass increase
of ~47 Da was observed which indicates the presence of a NO2 adduct and two protons on EA.
The data indicates that by becoming nitrated in the presence of a NOx radical donor, EA can
indirectly impact nitric oxide levels. This is because, even though EA does not react with NO
directly, it (partially) consumes total available NO by scavenging the reaction product between
NO and superoxide, i.e. peroxynitrite, as evidenced by the reaction product between EA and
model peroxynitrite mimic, TNM 30-32.
Cytotoxicity of EA and its protective effect against rotenone (RT) in PC12 cells was
determined using highthroughput screening assay. Cells exposed to increasing concentrations of
0.1 µM to 80 µM of EA exhibited a concomitant progressive cytotoxicity from 9% to 24% (Fig.
3.1C). However, up to 20 µM, there is no difference compared to untreated and vehicle controls
(as evaluated by the P-value). Statistical significance of 80 µM EA treatment against untreated
(Unt.) condition is also very low. In contrast, the addition of 5 µM rotenone (RT) induced 60%
cell death in the PC12 cell line after 24 h incubation (Fig. 3.1D). The administration of 10 µM
EA prior to 1 µM RT exposure resulted in ~20% cell death whereas administration of 1 µM RT
resulted in ~55% cell death (Fig. 3.1E). These data imply that EA pre-treatment was able to
rescue cell death by ~35% (P< 0.0001). Supplementary Figure 1 is a representative image of
untreated and 50 µM H2O2 (positive control) treated cells. P-value was calculated to determine
statistical significance of the results between two experimental sample groups. Morphology of
cells upon administration of EA prior to RT insult is further evidence of the protective aspects of
EA against RT-induced cell death (Fig. 3.1F).

Bright field compound microscopy picture

provides evidence of cellular morphology when cells were exposed to different conditions. The
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pre-treatment with 10 µM EA for 6 h enabled the PC12 cells to retain its morphology (as
untreated PC12) even after 1 µM RT insult. Cells exposed to 1 µM rotenone for 24 h showed
morphology similar to that observed in the positive control. Hydrogen peroxide (H2O2) was used
as a positive control for this experiment at a concentration of 50 µM (Fig. 3.1F). All the data
collectively indicates that ellagic acid pre-incubation is able to protect PC12 cells against
rotenone insult (Fig. 3.1).
Cell-based Reactive Oxygen and Nitrogen Species Scavenging Assays
The effect of EA on the total cellular ROS production was measured using 2’, 7’dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescence assay.

The cell-permeable

DCFH-DA reagent is reduced by cellular esterase to 2’, 7’-dichlorofluorescein (DCF) and is
trapped within the intracellular space. Additionally, several ROS agents such as hydrogen
.

peroxide, superoxide anion(O−
2 ), hydroxyl radical ( OH), as well as other peroxides, can also
oxidize DCF, resulting in the origin of the highly fluorescent DCF product33,34. Hence, an

increment in cellular fluorescence intensity reflects a proportional to a ROS increment. Relative
levels of intracellular ROS increased marginally at and above 20 µM EA administration relative
to the vehicle (~4%) and untreated controls (~6%; Fig. 3.2A). P-value is not significant up to 40
µM EA treatment when compared with untreated control. The corresponding levels of relative
ROS production were ~60-80% as a function of RT (Fig. 3.2B). Pre-administration of 10 µM EA
to the cell line was able to diminish relative ROS levels significantly from ~ 50% at 1 µM RT
alone to ~20% (EA pre-treatment + RT; Fig. 3.2C). The EA dependent diminution in ROS was
highly significant in comparison with 1µM RT treatment (P=0.0006). The membrane-permeable
4-amino-5-methylamino-2'',7''-difluorofluorescein (DAF-FM) diacetate is transformed by
cellular esterases to the fluorescent dye DAF-FM and becomes a direct indicator of intracellular
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nitric oxide (NO) production35. Our data showed significant increase of DAF-FM fluorescence
after 500 nM RT treatment in PC12 cells (P=0.0001; Fig. 3.2D). In contrast, pre-treatment with
EA dramatically lowers fluorescence levels indicating its RNS scavenging ability (P=0.0003).
Representative confocal microscopy images confirmed the fluorescence intensity of DAF-FM in
PC12 cells upon different treatments where panel i-iv stand for dimethyl sulfoxide (DMSO), 10
µM EA, 500 nM RT and 10 µM EA treatment prior to 500 nM RT exposure respectively (Fig.
2E).
Previous work has demonstrated that RT insult primarily results in mitochondrial stress
leading to efflux of NOx-based radicals3,36, thus, the results observed in the cell-dependent in
vitro analyses are consistent with the cell-independent in vitro analysis using the NOx donor
model. Our findings suggest that EA is able to mitigate elevated intracellular levels of ROS and
RNS (Fig. 3.2). Note that the exact mechanism nevertheless, is not delineated through cellular
studies. It is conceivable that NO levels, which constitute a part of the total RNS, may be
reduced in the presence of EA, albeit indirectly, through ring nitration of ellagic acid by
peroxynitrite (a product of nitric oxide and superoxide).
Inhibition of apoptosis and endoplasmic reticulum (ER) stress through EA intervention
The pathway by which rotenone insult leads to cell death was investigated (Fig. 3.3). The
addition of rotenone (500 nM) resulted in early stage apoptosis (Fig. 3.3A, B). However, prior
treatment of cells with 10 µM EA resulted in a notably rescue of cells from a rotenone-induced
apoptotic cell death. High statistical significance was found when the RT and EA pre-treatment +
RT treatment conditions were compared (P=0.0011). Cells treated with DMSO (0.1% v/v), 10
µM EA and untreated cells did not show substantial increase either in necrosis or apoptosis.
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H2O2 at a concentration of 50 µM was used as a positive control where substantial increase in
early and late apoptosis was denoted in the lower right and top right quadrants of the matrix plot.
Considering that cleavage of poly-(ADP-ribose) polymerase (PARP) is a hallmark for
apoptotic pathway activation37,38, we examined the ability of EA to prevent RT induced
apoptosis by measuring cleavage of native PARP-1(Fig. 3.3C, D). Cleavage of PARP, therefore
activation of apoptosis, occurred when cells were treated with 500 nM RT. This apoptotic
biochemical marker was evidenced by a dense band of the cleaved PARP-1 at 89 kD (Fig. 3.3C;
third lane from left). In a control, the addition of 10 µM EA induced ~15% cleavage of PARP-1
relative to DMSO treatment (Fig. 3.3D). Densitometric analysis of the protein bands revealed
that pre-treatment with EA for 6 h clearly protected PC12 cells from RT insult. About a 35%
reduction in PARP-1 cleavage was observed when compared to RT insult alone. These results
support the flow cytometric analysis performed to analyze the ability of ellagic acid to protect
PC12 cells against apoptosis and necrosis under RT insult.
As a part of their defense mechanism, cells often activate an apoptotic pathway when
they fail to circumvent ER stress. The role of RT as an ER-stressor has been documented in
previous studies39. To evaluate the role of EA in preventing RT mediated ER stress we checked
the expression of HSP-70 in PC12 cell (Fig. 3.3E, F). Over-expression of heat shock protein 70
(HSP-70) is an indication of ER-stress39. Treatment with 500 nM RT for 24 h showed a
significant increase in the expression of HSP-70 (P=0.0014) and pre-treatment with 10 µM EA
lowered the expression of HSP-70 to normal levels (P=0.0052; Fig. 3E). A high expression of
HSP-70 after RT treatment is an early indication that RT treatment commits the cell to the
apoptotic pathway39. However, our data indicate that a 10 µM EA pre-treatment was able to
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reduce HSP-70 expressed as a result of ER stress. These results suggest a rescue from the
apoptotic pathway (Fig. 3.3).
Mitigation of RT-induced S-nitrosylation of PDI and ubiquitination
It has previously been reported that nitrosative stress can compromise the catalytic
function of the oxidoreductase chaperone PDI. Specifically, the catalytic cysteines of PDI were
found to be S-nitrosylated upon RT insult7-11. Such a chemical modification of the housekeeping
machinery was found to be RT dependent and most importantly, neurotoxic18-21.
We examined the role of EA on mitigating levels of RT-induced S-nitroso PDI (SNOPDI) formation. Immunoglobulin G was used to pre-clean the cell lysate and pulled down using
SNO-cysteine BSA or TMT antibody and then detected with anti-PDI antibody in this study
(Pre-clean; Fig. 3.4A, C). Dithiothreitol (DTT; negative control) S-nitrosoglutathione (positive
control) treated PC12 cells were used to authenticate the experiment (Fig. 3.4A, C). Untreated,
DMSO, and 10 µM EA treated cell lysates show no formation of SNO-PDI while total PDI was
expressed and identified using an anti-PDI antibody (Fig. 3.4A, B). It is evident that pretreatment with 10 µM EA for 6 h was successfully capable of mitigating the S-nitrosylation of
PDI after 500 nM RT exposure for 24 h (Fig. 3.4A, B). Ratio of SNO-PDI versus total PDI was
calculated and plotted in the bar graph to depict true expression level of SNO-PDI upon different
treatment conditions (Fig. 3.4B, D). The different RT treatments showed a dose-dependent
response when treated with 100 nM and 500 nM RT. The two different RT conditions showed a
statistically significant difference (P=0.0053 & 0.0003 respectively) in the formation of SNOPDI when compared to untreated PC12 cells (Fig. 3.4B). Pre-treatment with EA showed a
significant reduction (P=0.0013) in RT induced SNO-PDI formation in PC12 cells (Fig. 3.4B).
TMT-switch assay also confirmed the SNO-PDI formation upon RT exposure (P=0.0018) and
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mitigation of same when pre-treated with EA (P=0.029; Fig. 3.4D). These results suggest that
ellagic acid is able to intervene in events leading to SNO-PDI formation within the cell line. We
reiterate that the actual mechanism by which EA mitigates SNO-PDI formation is not apparent
from the data gathered. It may be an outcome of NO interception via peroxynitrite formation.
Nevertheless, these data are consistent with previous cell-based and cell-independent in vitro
results (Fig. 3.1 and Fig. 3.2) indicating radical scavenging ability by the polyphenol.
Earlier studies confirmed the RT induced ER stress which is marked by over-expression
of HSP-70, an ER-resident protein39. In this study, we also showed that post-translational
modification of the catalytic domain of PDI upon RT treatment for 24 h leads to ER stress and
eventually activates the apoptotic pathway (Fig. 3.2, 3.3, 3.4). PDI, an ER resident chaperone,
play a major role in proper folding of proteins40. Misfolded proteins are tagged by ubiquitin to
guide them to proteosomal degradation system as a part of cellular defensive mechanism41.
Overburden of the proteosomal degradation system results in accumulation of ubiquitinated
proteins accompanied by increase in protein aggregation41. Using anti-ubiquitin antibody we
demonstrated a marked increase of ubiquitinated protein after 24 h RT treatment in insoluble
fractions (P=0.0129; Fig. 3.4E, F). However, prior treatment with EA dramatically decrease the
accumulation of ubiquitinated proteins (P=0.0375). Taken together, this data indicates that PDI
plays a major role in maintaining ER homeostasis and EA, a polyphenolic phytochemical, can
help to prevent ER stress.
Defining the role of EA in synphilin-1 and α-synuclein aggregation
SNO-PDI formation leads to aggregation of the minor Parkinsonian biomarker synphilin110. Therefore, we examined whether prevention of SNO-PDI formation by ellagic acid
intervention can mitigate the aggregation of synphilin-1. Transfected cells displayed high levels
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of GFP tagged syphilin-1 expression (Supplementary Fig. 3.2), with tendencies to be located in
the cytosolic and sometimes peri-nuclear position under different treatment conditions except the
empty pEGFP vector transfected cells (Fig. 3.5A). Panel-i indicates a relatively homogeneous
cytosolic distribution of EGFP in cells transfected with pEGFP-C2 plasmid alone. In contrast,
cells transfected with pEGFP- synphilin-1 constructs show a punctuated (or speckled) cytosolic
distribution of green fluorescent signal (Panel-ii). Cells, treated with the 10 µM EA alone (Paneliv) did not differ in the expression of EGFP-synphilin-1 as compare to vehicle treatment
(DMSO; Panel-iii). When cells were exposed to 500 nM rotenone for 24 h, cytosolic aggregation
of synphilin-1 was clearly evident (Panel-v). Pre-treatment of cells with 10 µM EA 6 h prior to
500 nM rotenone exposure resulted in a markedly diminished level of synphilin-1 aggregation
(Panel-vi). These findings reveal that cells under rotenone induced nitrosative stress apparently
increased the aggregation of EGFP-synphilin-1 fused protein by forming cytosolic inclusion
bodies. EA showed to be able to mitigate the aggregation of the fused EGFP-synphilin-1 protein
to a statistically significant level (P=0.0310) when PC12 cells were treated with 10 µM EA prior
to rotenone insult (Fig. 3.5B).
α-synuclein is a major Parkinsonian biomarker and the primary constituent within Lewy
neurites14-17. We examined the expression level of α-synuclein upon rotenone toxicity (Fig.
3.5C). Panel-ii shows cytosolic homogeneous distribution of expressed α-synuclein when
transiently transfected with pCMV6 plasmid containing α-synuclein genetic sequence. In
contrast empty pCMV6 plasmid transfection (Panel-i) showed no expression of α-synuclein
relative to panel-ii. Disruption of the homogeneous distribution of expressed α-synuclein protein,
an evident of cytosolic aggregation, was clearly seen when transiently α-synuclein transfected
cells were exposed to 500 nM rotenone for 24 h (Panel-v). DMSO (0.1% v/v) and 10 µM EA
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treatment (Panel-ii and iv respectively) for 24 h showed no deviation in expression level or
distribution when compared with the untreated condition (Panel-ii). α-synuclein transfected
PC12 cells pre-treated with 10 µM EA for 6 h prior to 24 h rotenone exposure are shown in
panel-vi. 10 µM EA treatment markedly reduced (P=0.0161) the aggregated α-synuclein
expression (~15% relative to RT treatment) indicating its potency to nullify the nitrosative stress
imposed by rotenone exposure (Fig. 3.5D).
EA mitigates the formation of RT-induced α-synuclein:synphilin-1 Lewy body-like inclusions
The Parkinsonian biomarkers α-synuclein and synphilin-1 are found to co-localize in PD
patient’s brains14-17. In order to investigate whether rotenone toxicity implies α-synuclein and
synphilin-1 aggregation, PC12 cells were transfected with plasmid constructs carrying tagged
fluorescence proteins and monitored via confocal microscopy (Fig. 3.6). Synphilin-1 gene was
fused with GFP sequence (green signal) in pEGFP plasmid, whereas α-synuclein gene (red signal
as secondary antibody was conjugated with texas red probe) was inserted in pCMV6 plasmid.
Co-localization of α-synuclein and synphilin-1 was detected in cells treated with 500 nM RT as
evidenced by the presence of the yellow punctuated pattern (Fig. 3.6D). The yellow pattern is
the result of the superimposition of the green and red signal. The co-localization of these two
biomarkers is an accepted Lewy body14-17. The aggregate pattern, as well as co-localization was
diminished when transfected PC12 cells were pre-treated with 10 µM EA for 6 h prior to a 500
nM RT treatment for 24 h (Fig. 3.6E). The formation of Lewy body-like aggregates visualized
as inclusions was indicated by a white arrow in each figure except figure 3.6A (Cells were
transfected with empty pEGFP and empty pCMV6 vector in a 1:1 ratio). A Lewy body-like
inclusion is shown as an inset (i) in the right most section of each panel zoom in (3X) (Fig. 6).
Around a two fold increase in aggregation of synphilin-1 and α-synuclein (when co-expressed)
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(P=0.0207 & P=0.0049 respectively) is clearly shown upon 500 nM RT exposure relative to the
10 µM EA treatment prior to RT exposure (Fig. 3.6F). Results graphed as bar diagram indicate
fluorescent intensity where red bar represents α-synuclein expression (red channel) and green bar
represents synphilin-1 expression (green channel; Fig. 3.6F). In the representative bar diagram
X-axis depicts different treatment conditions and Y-axis represents fluorescent intensity (Fig.
3.6F). Aggregation of co-expressed synphilin-1 and α-synuclein (P=0.0050 & P=0.0421
respectively) after rotenone exposure for 24 h in PC12 cell line was convincingly reduced by
pre-treatment with 10 µM ellagic acid. Co-localization of these two proteins was confirmed by
Zen 2009 software (Supplementary Fig. 3.3). We further counted the cytoplasmic inclusion
bodies in PC12 cell co-transfected with synphilin-1 and α-synuclein (Fig. 3.6G; Supplementary
Fig. 3.4). The 500 nM RT treatment increased the number of inclusions dramatically relative to
the vehicle control (DMSO) treatment (P=0.0011; Fig. 3.6G). However, cells treated with 10 µM
EA prior to RT exposure, had a significantly lower count of inclusion bodies (P=0.0164). This
series of experiments indicate that EA possesses protective activity against rotenone toxicity by
preventing the aggregation of synphilin-1 and α-synuclein or α-synuclein:synphilin-1 Lewy
body-like inclusions in PC12 cells (Fig. 3.6).
EA binding to Human Serum Albumin (HSA)
HSA is a cargo protein for different biologically active small molecules42. Reversible
binding of a small molecule into the hydrophobic pocket of HSA can provide long shelf life as
well as can help the active molecule to release into the gut for absorption42. In HSA, the
fluorescence intensity due to the tryptophan residue (Trp-214) is proportional to the protein
concentration ([P]). At the same time, this fluorescence is proportionally affected by the binding
of other molecules ([L]) such as EA, thus, providing a method to determine protein-ligand
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complex concentration ([PL]) as well as [P] and [L], ultimately providing a technique to
determine binding constants43-45. The Langmuir isotherm data indicates that EA reversibly binds
to HSA (Fig. 3.7). The Kd value for the binding of EA to HSA was experimentally determined to
be Kd = 1.43 × 10−7 M. This reversible binding to HSA suggests that EA has an increased

probability of an effective bioavailability in the human body.
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3.4 Conclusion
The cytotoxicity of EA and its prophylactic effects against RT–induced nitrosative insult
were determined through differential nuclear staining cytotoxicity assay. EA was found to have a
low cytotoxic effect on the model PC12 cell line and a protective effect against RT cytotoxicity.
Our study demonstrated that RT-induced apoptotic death evidenced by PARP-1 cleavage and
flow cytometric analysis was significantly reduced in the presence of EA. EA significantly
mitigated the elevated intracellular levels of ROS and RNS induced by rotenone-inhibition of the
mitochondrial respiratory chain, an important finding for PD prevention and other
neurodegenerative disorders associated with intracellular ROS, RNS and ER stress. In vitro data
indicate that EA gets nitrated in the presence of NOx donors. These results translate to the cell
line where the presence of EA resulted in the mitigation of RNS induced S-nitrosylation of PDI.
The mechanism by which SNO-PDI formation is mitigated by EA could be through the
consumption of NO generated peroxynitite 30,32. These data represent an important finding in the
methods designed to prevent pathogenesis of sporadic PD. EA intervention was also found to
play an important role mitigating the formation of α-synuclein and synphilin-1 aggregates as well
as α-synuclein:synphilin-1 Lewy body-like aggregates by maintaining ER homeostasis. In
addition, EA was found to have a strong interaction with HSA, which has implications in drug
bioavailability.
In conclusion, our results advance the neurodegeneration field by mapping the catalytic
failure of cellular housekeeping machinery to PD and also establish a preventative approach
against the disease. The reported results can be used for further research in related neuropathies
whose onset may be related to the dysfunction of the cellular homeostasis apparatus. It is
especially noteworthy that EA has no known side effects and crosses the blood-brain barrier28.
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Fig. 3.0. Proposed mechanism of Rotenone-induced S-nytrosilation of PDI results in lewy bodylike aggregates.
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Fig. 3.1. Ellagic acid (EA) scavenging NO radical in vitro (A, B). Cytotoxicity and protective
ability of ellagic acid on PC12 cell line against rotenone insult (C-F). The cytotoxicity and
preventive effect of EA was testified on PC12 cell line, measured by using differential nuclear
staining (DNS) assay adapted to high throughput screening (HTS). Cytotoxicity of EA at
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different concentration after 24 h of treatment (C). Statistical significance compared with
untreated are illustrated as P-value. Cytotoxicity of rotenone (RT) at different concentration after
24 h of treatment (D). Preventive effect of EA against RT toxicity in PC12 cells (E). Bright field
images of PC12 cells taken by using compound microscope after different treatments, as
indicated below of each image (F). White scale bar in each image indicate 50 µm distances. Data
were analyzed by using BD AttoVision™ v1.6.2 software. Each experimental point was assessed
in quintuplicate.

Fig. 3.2. EA treatment attenuates reactive oxygen species (ROS) and reactive nitrogen species
(RNS) production in PC12 cell. The ROS levels were measured by DCFH-DA staining assay and
analyzed at 24 h after EA treatment (A). The levels of ROS in EA treated cells are presented as
fold change compared to the levels in positive control cells. The levels of ROS in RT treated
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cells are presented as fold change compared to the levels in positive control cells (B). The ROS
quenching activity of EA pretreated PC12 cells followed by 24 h of RT exposure are presented
as fold change compared to the levels in positive control cells (C). RT increases RNS production,
which is attenuated by EA pre-treatment (D). Representative confocal images confirmed the
intracellular RNS production on different treatment (i-DMSO; ii-10µM EA; iii-500 nM RT; ivEA+RT; E). Statistical significance compared with untreated are illustrated as P-value. Each bar
represents the average of five replicas and the error bars their standard deviation.

Fig. 3.3. Anti-apoptotic ability of EA through maintaining endoplasmic reticulum (ER)
homeostasis. Representative flow cytometric histograms used to measure apoptosis/necrosis
distribution: untreated control, vehicle control (DMSO), positive control (50 µM H2O2), EA,
rotenone and pretreatment with EA and then 24 h rotenone exposure (A). Quantification of
apoptotic-necrotic assay under previously mentioned conditions (B). Protective effect of EA (10
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µM) against rotenone (500 nM) induced poly (ADP-ribose) polymerase (PARP) cleavage,
hallmark of apoptosis progression, in PC12 cells (C). PARP-1 cleavage bands were
densitometrically analyzed via western blot analysis using Image J software (D). Rotenone (RT)
induced over-expression of heat shock protein 70 (HSP70), an ER resident protein, is mitigated
by 10µM EA pre-treatment (E). Expression of ER-stress marker protein, HSP70, is quantified
under different treatment using Image J (F). Statistical significance between samples is
illustrated as P-value (n=3).

Fig. 3.4. Evaluation of SNO-PDI formation and accumulation of ubiquitinated proteins upon
different treatment. Ellagic acid (EA) successfully mitigate the rotenone (RT) induced SNO-PDI
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formation (A-D). SNO-PDI signals were detected after pull down the IgG-agarose beads using
SNO-CYS BSA antibody then treated with PDI antibody to visualize (A). TMT-switch assay
confirm the formation of SNO-PDI after RT treatment and the potential of EA (C). Densitometry
analysis of SNO-PDI band (B, D). RT-induced accumulation of ubiquitinated proteins in the
insoluble fraction of cell lysate is reduced after 10 µM EA pre-treatment (E, F). All the
densitometry analysis were done using Image J software from three independent tests indicated
as mean ± S.D. Statistical significance among pairs of samples is annotated as P-value (n=3).

Fig. 3.5. Role of ellagic acid (EA) in GFP-tagged synphilin-1 and α-synuclein aggregation (AD). Cells transfected with pEGFP-C2 empty vector or pCMV6 empty vector (Panel-i), untreated
cells (Panel-ii), cells treated with DMSO 2.5 v/v (Panel-iii), cells treated with 10 µM EA (Paneliv), cells exposed to rotenone (RT) (500 nM) for 24 h alone (Panel-v) and cells treated with
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10µM EA for 6 h before exposed to rotenone (500 nM) for 24 h (Panel-vi) are the different
conditions used for this study (A, C). Confocal microscopy images of PC12 cells reveal the
presence of cytoplasmic aggregates in cells transfected with pEGFP-tagged synphilin-1 plasmid
under different treatment (A). Confocal fluorescence images of PC12 cells revealed the presence
of α-synuclein cytoplasmic aggregates under different conditions (C). All the cells were
counterstained with DAPI to stain the nucleus (blue color). White arrow indicates expression of
synphilin-1/ α-synuclein protein (A, C). Quantification of synphilin-1 (Green channel) or αsynuclein (Red channel) in PC12 cell line upon different treatment using Image J software from
n=200 cells indicated as mean ± S.D (B, D). Statistical significance between pairs of samples is
illustrated as P-value. Each scale bar represents 10µm. Each experiment was assessed in
triplicate.
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Fig. 3.6. Co-Expression of α-synuclein and synphilin-1 in PC12 cells under rotenone (RT)induced aggregation and mitigation through ellagic acid (EA) intervention. Cells transfected with
pCMV-6 and pEGFP empty vector (A). PC12 cells transfected with α-synuclein and synphilin-1
(2 µg each per condition) and treated with DMSO 0.02% v/v (B). PC12 cells were treated with
10 µM EA for 24 h (C). Cells exposed to 500 nM RT for 24 h (D). Cells pretreated with 10 µM
EA for 6 h, then exposed to 500 nM rotenone for 24 h (E). Synphilin-1 was tagged with GFP
showing green color and α-synuclein is shown in red color. White arrow indicates co-localization
of α-synuclein and synphilin-1 (Yellow color; representative of Lewy body-like inclusion; A-E).
Inset-part (i) of each figure at extreme right panel zoomed in the co-localization of α-synuclein
and synphilin-1 (1.5X magnification). DAPI was used to stain the nucleus (blue). Quantification
of α-synuclein expression (Red channel) and synphilin-1 (Green channel) in PC12 cell line upon
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different treatment using Image J software from n=200 cells indicated as mean ± S.D (F).
Statistical significance compared with untreated are illustrated as P-value. Each scale bar
represents 10µm. Each experiment was assessed in triplicate. Total number of cytoplasmic
inclusion body significantly elevated after RT treatment although EA pre-treatment decrease the
inclusion body count in PC 12 cell (G; Supplementary Fig. 3.4).

Fig. 3.7. Fluorescence emission profiles for the binding of ellagic acid (0 to 140 µM) to native
human serum albumin (20µM). A) Solid line represents a theoretical one-site binding profile.
Fluorescence parameters were: λexc = 280 nm and λem = 310 and 340 nm. All solutions were at
200 mM Tris-HCl, 1 mM EDTA, pH 7.5 and were prepared at room temperature 24 ± 1 °C.
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3.5 Supportive Information
Live PC12 cell imaging to determine cytotoxicity (Supplementary Fig. 3.1), over-expression of
α-synuclein in PC12 cell (Supplementary Fig. 3.2), co-localization quantification of α-synuclein
and synphilin-1-GFP (Supplementary Fig. 3.3), quantification of inclusion bodies in PC12 cell
(Supplementary Fig. 3.4), Specificity of S-nitrosocysteine antibody (Supplementary Fig. 3.5) and
analytical data (Mass spectrometry analysis) of ellagic acid and TNM (Table S1)

Supplementary Fig. 3.1. Live-cell images utilized to quantify cytotoxicity on PC12 cells.
Untreated cells as negative control (A). Cells treated with 50 µM H2O2 as positive control (B).
Total numbers of cells were labeled with Hoechst, emitting blue signal (left panels); whereas
dead cells were labeled with propidium iodide, emitting red signal (middle panels). Merged
images (right panels) are depicting cells in blue (live) and cells in magenta color (dead) as an
outcome of co-localization of red (PI) and blue (Hoechst) colors. Images were acquired and
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analyzed utilizing a BD Pathway 855 Bioimager system, assisted with BD AttoVision v1.6.2
software. The scale bar is equal to 100 µm.

Supplementary Fig. 3.2. Expression of α-Synuclein in transfected PC12 cells (A). Extracts from
cells transfected with the empty vector pCMV6 (Lane 1), non-transfected cell (NTC; Lane 2),
and transfected with pCMV6-α-synuclein (Lane 3). Quantification of relative intensity of αsynuclein bands using ImageJ software are depicted as average and standard deviation from
triplicates (B).
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Supplementary Fig. 3.3. Co-localization of synphilin-1-GFP and α-synuclein in PC12 cells.
Merged dual-channel image (green and red ) from doubly-labelled transfected PC12 cell with
two plasmid constructs, carrying a Synphilin-1-GFP or α-Synuclein are shown respectively (A).
Note that in the image in panel A, two region of interest (ROI; squares) are included. The
numbers at the bottom of each ROI are overlap co-localization coefficient values of the
delimitated areas according with Manders.1 Panels B and C are the co-localization dot plot
histograms of the ROIs localized in top left and center in panel A, respectively, where each pixel
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is presented as a dot. Pixels with well co-localized signals, appear in the quadrant 3 (top right) of
the histograms (B and C), as a scatter diagonal population. Overlap coefficient values range from
0 to 1; a value of 1 represents 100% of co-localization of both fluorescence signals, whereas 0
represent complete absence of co-localization. ZEN 2009 software was utilized to perform the
overlap coefficient analysis.
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Supplementary Fig. 3.4. Quantification of total co-localized aggregates (mimic of Lewy body)
of α-synuclein and synphilin-1 expressed in PC12 cells under different treatment conditions.
Transfected PC12 cells were untreated or stressed with different treatments. Cells transfected
with α-synuclein and synphilin-1 then treated with DMSO 0.02% v/v (A); cells treated with 10
µM EA (B); cells exposed to 500 nM rotenone for 24 h alone (C); pre-treatment with 10 µM EA
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for 6 h and then exposed to rotenone for another 24 h (D). All the cells were counterstained with
DAPI to delimitate the nucleus (Blue color). Yellow arrows indicate the presence of aggregates.
Synphilin-1 was tagged with GFP showing green color and α-synuclein is shown in red color.
Yellow color represents co- localization of α-synuclein and synphilin-1. Extreme right panel of
each figure represents the co-localization of α-synuclein and synphilin-1 indicated as white spot
using Image J co-localization software (n=200). The scale bar represents 50 µm. Each
experiment was repeated in triplicate.

A

B

Supplementary Fig. 3.5. Detection of SNO-PDI in rotenone treated PC12 cell line. A) Western
blot signals of SNO-PDI in PC12 cell after treatment with or without rotenone and ellagic acid.
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To prepare positive and negative control samples, cells were incubated for 30 minutes at room
temperature with 200 µM S-nitrosoglutathione or DTT, respectively. SNO-PDI signals were
detected using SNO-CYS BSA antibody after pull down the IgG-agarose beads treated whole
cell lysate against PDI antibody. Proteins were separated in 12% SDS-PAGE, blotted and
visualized with specific antibodies. B) The total PDI bands were detected using specific
monoclonal PDI antibody. The experiment was repeated in triplicate.

Supporting Information
Table S1. EA as a NO radical scavenger: in vitro study
ESI negative mode
ESI negative mode after TNM use
Mass
Identity
Mass
Identity
301.232

[M - H]

301.197

[M - H]

602.469

[2M – H]

348.817

[M- H + NO₂]
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Chapter 4:
Beta amyloid (25-35) induced Lewy body-like inclusions formation mediated
by S-nitrosylation of PDI.
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4.1 Introduction
Alzheimer’s disease, a form of irreversible dementia characterized by slow decline of
cognitive function, currently affects around 27 million people worldwide1. Now in the United
States AD is the sixth leading cause of death, which on an average occurring nine years after
diagnosis1-4. Transformation from alpha helical to beta sheet dominated structure of different
notorious protein is the key event to ignite neurodegenerative diseases. Pathological findings of
human AD brain confirm the involvement of extracellular beta-amyloid (Aβ) plaques and
hyperphosphorylated intracellular tau tangles5,6. Cell surface receptor protein APP is the
precursor of Aβ as a result of β-secretase and γ-secretase activity7. According to amyloid cascade
hypothesis, an increase in the Aβ42/ Aβ40 ratio alter the ionic homeostasis and oxidative stress
leading to hyperphosphorylation of tau; tangle formation ultimately causing axonal dysfunction
and neuronal cell death

5,8,9

. Interestingly different fragment of Aβ (eg. 1-28; 25-35; 34-42)

showcase same bio-physical and toxicological property as the full length version of Aβ (16-18).
Aβ (25-35) fragment is more toxic than the other fragments because of its beta-sheet fibrils
formation and considered as the active domain of Aβ (1-42)10-12.
The late onset characteristic of AD, in spite of the presence of the mutation since birth,
gave rise to speculation of prion like self-propagating Aβ protein aggregates throughout the
brain13,14. Several evidences argue that Aβ is a prion13,15-17. There are direct confirmation of the
presence of Aβ prions, demarcated as Aβ aggresome adept of self-propagation within the
brain16,17. Though it is not clear what accounts for the different potencies of the brain-derived
and synthetic beta-amyloid. Failure of the ubiquitin-proteasome system that normally degrades
misfolded proteins leads to the formation of so-called aggresomes, pericentriolar inclusions18,19.
These proteinaceous aggregates can induce cytosolic assembly of aggregation-prone soluble
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proteins through seeding-like mechanism that share similarities with prion propagation14-16,20.
We hypothesize that peptide fragment inside Aβ (1-42), which is (25-35), will also act like prion.
Readily soluble Aβ (25-35) forms aggregate which can be fibriler or oligomeric in nature
depending on the pH of the solvent. A beta (25-35) is the smallest peptide segment, which can
replicate the same kind of physiochemical and pathological condition as long a beta (1-42)
peptide.
Neuro-pathological findings of patients with PD reveal the presence of α-synuclein, an
amyloidogenic protein, within Lewy bodies, making it a key biomarker implicated in the
pathogenesis of PD21. The minor Parkinsonian biomarker, synphilin-1 also found to be coexisted
with α-synuclein in the Lewy body 21. Lewy body pathology is also found in a large number of
AD patients, also commonly known as Lewy body variant of Alzheimer’s disease (AD-LBV)22.
Unfortunately, AD-LBV patients showed accelerated cognitive decline as well as early demise
rate 22. Also, the overlapping clinical and pathological features of brain amyloidogenesis in AD
and PD patients gave rise to the speculation of mechanistic connection in between AD and PD
etiology21-24. Previous study suggested that Aβ (1-42) oligomer can influence the folding of
amyloidogenic protein via cross-seeding mechanism15,24. It has also been reported that the Aβ (142) oligomer can induce the formation of oligomeric α-synuclein, but in cell free system24.
Change in expression and aggregation of α-Synuclein upon Aβ (25-35) incubation will lead us to
understand the complexity of AD and alleged relation with PD. As there is little or no clear idea
of the mechanism by which Aβ (25-35) exerted its influence on amyloidogenic proteins, we
decided to ask why this phenomenon is taking place.
Excess reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation,
has been demonstrated with high importance in AD and PD (Parkinson’s disease)19,25,26. There is
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an emerging body of evidence suggesting that Aβ (1-42) could induce apoptotic cell death via
ROS stress in a variety of cells26. The Aβ (25-35) peptide fragment also follows the same trend
in ROS production as of Aβ (1-42)11. But the role of Aβ (25-35) in RNS production inside the
cell is unclear. It is been well established that nitrosative stress plays an important role in
apoptosis19, therefore, understanding the interface between nitrosative stress generation and
apoptosis, is pivotal in neurodegenerative diseases research. Several studies showed that proteindisulfide isomerase (PDI), a key ER-resident chaperone protein, helps in protein folding. PDI get
chemically modified by RNS to form S-nitroso-PDI in AD and PD brains27-29. Excess amount of
RNS production is capable of promoting ER stress by inactivating the catalytic sites of
chaperone proteins. Recent study showed not only the modulation of enzymatic activity but
redistribution of PDI upon posttranslational modification as well30. Reports on the
immunoreactivity of PDI with Lewy body (PD pathology) as well as neurofibrilar tangles (AD
pathology) give rise to the speculation of direct involvement with AD and PD specific proteins3134

. It is interesting to note that amyloidogenic protein, α-synuclein often found at the wrong side

of different neurodegenerative disease namely: PD, PD with dementia, Lewy body variant
disease and AD-LBV22-24. We wanted to investigate the change in PDI expression and its
modification, if any, to explain the cause of Aβ (25-35) induced stress in SHSY-5Y cell.
So, we hypothesize that posttranslational modification of PDI as a function of betaamyloid (25-35) aggregosome, can lead to aggregation of synphillin-1 and α-synuclein when
expressed or co-expressed by dopaminergic cells. In addition, Aβ (25-35) peptide fragment could
lead to ER stress mediated activation of apoptotic pathway through SNO-PDI formation. We
also hypothesized that Aβ (25-35) can influence the interaction of PDI and synuclein protein. To
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test our hypotheses, we generated dopaminergic cell line that expresses GFP-tagged synphilin-1
protein and α-synuclein either alone or in combination.
4.2 Experimental Procedure
Genetics
Beta amyloid (25-35) and tagged with Hilyte-488 (Hilyte™ Fluor 488 - Gly - Ser - Asn Lys - Gly - Ala - Ile - Ile - Gly - Leu - Met - OH) were purchased from AnaSpec Inc (San Jose,
CA).

Commercially

sourced

reagents

are

following:

4-amino-5-methylamino-

2'',7''-

difluorofluorescein diacetate (DAF-FM diacetate) and Lipofectamine® LTX with Plus reagent
(Life technologies); anti-PDI antibody (Abcam); polyclonal anti-S-nitrosocysteine antibody
(Abcam); normal rabbit IgG (SantaCruzBio); mouse monoclonal anti- GAPDH (Glyceraldehyde
3-phosphate dehydrogenase) antibody and rabbit monoclonal anti-PARP antibody (Cell
Signaling Technology, Danvers, MA); Annexin V-FITC apoptosis kit (Beckman Coulter, Miami,
FL), anti-mouse and anti rabbit horseradish peroxidase (HRP)-conjugated (KPL Biomedical);
Hoechst 33342 fluorescent stain (Invitrogen, Eugene, OR); Propidium Iodide (PI) (Invitrogen,
Eugene, OR); Human neuroblastoma cell line SH-SY5Y (ATCC, Manassas, VA). Cells were
transfected with the pEGFP-C2 or synphilin-1/pEGFP-C2 and pCMV6 or α-synuclein/pCMV6
plasmid as previously described 19,25.
Cell culture and transfection
SH-SY5Y cells were cultured in DMEM and Ham’s F12 media mixture (1:1)
supplemented with 10% fetal bovine serum (Atlanta Biologicals) and 1% penicillin–
streptomycin (Sigma). Cells were grown at 37°C in humidified 5% carbon dioxide atmosphere.
SH-SY5Y cells (1 × 106 cells/well) were seeded onto suitable plates according to the need of the
experiment and incubated for 12 h. Cell transfections were performed, after reaching 60-70%
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confluency, with pEGFP-C2 control (without insert) or pEGFP-C2 carrying the fusion protein
GFP-synphilin-1, and pCMV6 control or pCMV6 inserted with α-synuclein as per
recommendation of manufacture; Lipofectamine® LTX with Plus™ Reagent (Lifetechnologies,
NY). After transfection, the cells were incubated overnight to allow expression of proteins.
Detection of intracellular RNS and ROS
DAF-FM is an oxidation-sensitive fluorescent dye where 4-amino-5-methylamino- 2'',7''difluorofluorescein (DAF FM) is the fluorescent part. Then, cells were harvested (5000/well) on
96-well plate, washed with PBS, and analyzed immediately with a micro-plate reader
fluorometer (Labsystems Fluoroskan Ascent) using excitation at 485 nm and emission at 518 nm.
DCFH-DA is an oxidation-sensitive fluorescent dye where 2’, 7’-dichlorofluorescein (DCF) is
the fluorescent part. Cells were loaded with the dye by exposing them to 10 µM MDCFH-DA for
20 min at 37oC. The cells were then harvested, washed with PBS, and analyzed immediately with
a microplate reader fluorometer (Labsystems Fluoroskan Ascent) using excitation at 485 nm, and
emission at 518 nm. Each data point was assessed in quintuplicate19. Images were captured using
Carl Zeiss LSM 700 microscope, 20X lens.
Dynamic Light Scattering studies
For the dynamic light scattering (DLS) measurements the commercial instrument
Zetasizer Nano-S was used (Malvern Instruments Ltd, UK; www.malvern.com). He-Ne laser
(633nm) was used as a light source for precise particle sizing in the range of 0.3nm – 10.0
microns (diameter). The aggregation kinetics of Beta amyloid (25-35) was studied by DLS. A
solution for the experiment was prepared using double distilled water. The buffer was placed in a
cuvette and pre-incubated for 10 min at room temperature. The process of aggregation was
begun by the addition of an aliquot of the Beta amyloid (25-35) from the stock solution.
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Flow cytometric assay
SH-SY5Y cells were seeded on 24-well micro plate at density of 20,000 cells/ well,
and cultured as described. Cells were treated with different concentrations of Amyloid beta
(25-35) alone, to determine its possible cytotoxic effect. As control for non-specific effects,
distilled water vehicle control, as contained in the experimental samples, was included at
final concentration of 0.1% v/v. 19. Cells from each individual well were collected, washed
and processed essentially as described previously19,25. Briefly, cells were concurrently
stained by re-suspending them in a solution containing Annexin V-FITC, and PI dissolved
in 100 μl of binding buffer (Beckman Coulter, Miami, FL). After incubation for 15 min on
ice in the dark, ice-cold binding buffer (400 μl) was added to the cell suspensions, gently
homogenized, and immediately analyzed by flow cytometry. The percentage of total
apoptotic cells per sample is annotated as the sum of both early and late stages of apoptosis
(Annexin V-FITC positive), bottom right quadrant and top right quadrant, respectively. For
each sample, approximately 10,000 individual events were acquired using flow cytometer
(Cytomics FC 500; Beckman Coulter, Miami, FL), and data was analyzed with CXP
software (Beckman Coulter, Miami, FL). Every experimental point, as well as all controls,
was assessed in quintuplicate.
Biochemistry
Total cell lysates were prepared by washing the cells with cold Tris-buffered saline,
collected by centrifugation (3003g, 5 min at 4°C, and extracted by sonication in buffer
containing 10 mM Tris–HCl (pH 7.4), 10 mM EDTA, 0.5% (v/v) SDS and protease inhibitors
(Sigma). Total protein concentrations were measured using a bicinchonic acid kit (Pierce,
Rockford, IL) and BSA as standard. Equal amounts of protein (approximately 10 µg per lane)
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were separated using SDS-polyacrylamide gel electrophoresis, and then transferred to polyvinyl
difluoride (PVDF) membranes. Blots were incubated in blocking buffer (5%, w/v, dried
skimmed milk in Tris-buffered saline, pH 7.4, and 0.1% Tween 20) followed by incubation with
anti-PARP/ anti-synphilin-1/ α-synuclein rabbit polyclonal antibody (1:1000), or anti-GAPDH/
anti-actin (1:1000/ 1:2500 dilution) diluted in blocking buffer for 1 h followed by horseradish
peroxidase (HRP)-conjugated goat anti-rabbit in 1% BSA/TBST for 30 min. Chemiluminescence
(ECL-plus or SuperSignal West Pico Chemiluminescent Substrate) was used according to the
manufacturer’s instructions (Amersham or Pierce Biotechnology Inc.). GAPDH/actin was used
as housekeeping protein loading control.
Confocal microscopy and immunocytochemistry
Cells transfected with vector or EGFP-synphilin-1/ α-synuclein were washed after
treatment, fixed with 4% paraformaldehyde in PBS, stained with DAPI and mounted under
ProLong antifade medium (Molecular Probes). To stain for synphilin-1/ α-synuclein, cells were:
fixed as above, permeabilized with 0.1% (w/v) saponin in PBS, blocked with PBS plus 5% goat
serum, 5% FBS and 0.1% TWEEN 20, followed by incubation with primary antibody (overnight
at 4ºC) and secondary rhodamine-conjugated goat anti-mouse (1:10000; KPL Biomedical), and
DAPI staining. Fluorescence confocal images were captured utilizing LSM 700 confocal
microscope and assisted with ZEN 2009 software (Zeiss, New York, NY)19.
Co-immunoprecipitation
Cell lysate was prepared following the same procedure as western blot25. Proteins were
separated in 12% SDS-PAGE, blotted and visualized with selected antibodies. 200 µl lysates (1
mg/ml) of SHSY-5Y cell homogenates were pre-cleaned by 50 µL protein G agarose (Santa
Cruz Biotechnology) to detect S-nitrosylated PDI, as previously reported19. In short, 2.5 µg
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polyclonal anti-S-nitrosocysteine antibody (Abcam) was added to the supernatant, and incubated
for 1 h at 4°C. After centrigugation, pellet was washed three times with 1 mL chilled TBS
containing 1% (v/v) tween-20 and 1 mg/ml BSA and 0.5 M Tris–HCl respectively. Following the
final centrifugation step, the pellet was re-suspended in SDS sample buffer, subjected to western
blot analysis, and immunostained for PDI as described previously19. Chemiluminescence (ECLplus or SuperSignal West Pico Chemiluminescent Substrate) was used according to the
manufacturer’s instructions (Amersham or Pierce Biotechnology Inc.). Experiment was assessed
in triplicate.
Co-immunoprecipitation, immuno-fluorescence and inclusion body quantification
To quantify protein level detected by western blot, we used the Image J software. In order
to quantify the fluorescence of expressed proteins, random fields for each tested condition were
obtained at the same magnification (63X oil immersion, zoom 1.5X). Then, a region of interest
(ROI) with an area of 400 pixels (20X20) was chosen, and the average intensity of fluorescence
within the ROI was measured in the cytosol of every transfected cell present in the field. Over
100 cells were analyzed for each condition. The values obtained were averaged and were plotted
using a bar graph. The results were obtained from more than, or equal to three independent
experiments. To count the cells with inclusion body, we used colocalization finder in Image J
software. Randomly selected 10 different fields (100 cells / field) were counted in three different
sets of experiments to avoid the prejudice (Supplementary Fig.4.1).
Statistical calculation
Every data point was collected independently and in triplicate. To note experimental
viability and variability, data were presented as the average with its corresponding standard
deviation. Statistical analysis was performed using two-tailed paired Student's t-tests to denote
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the statistical significance of variances between experimental samples and their corresponding
controls. To identify if there is a significant difference between two groups, a value of P< 0.05
was considered significant. We denote the actual P-value in each graph wherever needed.
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4.3 Results and discussion
RNS mediated apoptosis in SH-SY5Y upon Aβ (25-35) insult
Aβ (25-35), an internal fragment of Aβ (1-42), was readily aggregated when it came in
contact with distilled water molecule (Fig. 4.1A) because of the hydrophobic property11,20,26.
Average diameter of the aggregates was measured as 162 nm ± 37.32 using dynamic light
scattering under controlled condition. Estimated molecular weight of the aggregates was 9.79
kDa when added to dist. water (1:100), whereas the molecular weight of a single peptide
fragment is 1060.3 Da.
SH-SY5Y cell line, designed to mimic the dopaminergic neuronal cell, was used for our
whole study. We performed flow cytometry based cytotoxicity analysis of Aβ (25-35) peptide
fragment in SH-SY5Y cells using PI dye (Fig 4.1, B and C). Percentage of cell death increased in
a dose dependent manner from 1 µM to 50 µM (P=0.0006) (from ~11% at 1 µM to ~42% at 50
µM Aβ (25-35) after 48 h incubation at 37ºC). Quantitative analysis (Fig. 4.1C) suggest that even
5 µM aggregated Aβ (25-35) is significantly toxic, whereas 50 µM is highly toxic to the cell
relative to the untreated condition (P=0.0069 & P=0.0003 respectively).
The pathway by which Aβ (25-35) insult leads to cell death was also investigated (Fig.
4.1, D-G). Annexin V-FITC, an apoptotic marker protein, and PI (1:1 mixture) were used in flow
cytometry based analysis of apoptosis and necrosis.

Cells were treated with different

concentrations of Aβ (25-35) (1 µM, 5 µM, 10 µM, 20 µM and 50 µM) for 24 h at proper cell
growth conditions. 50 µM H2O2 was used as positive control where substantial increase in early
and late apoptosis denoted in lower right and top right quadrant of the matrix plot (Fig. 4.1D; top
row second histogram from right). Cells treated with distilled H2O (0.1% v/v), 1 µM Aβ (25-35)
and untreated cells did not show substantial increase either in necrosis or apoptosis. However, we
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found high statistical significance when compared between 1 µM and 50 µM treatment
conditions (P=0.0309) in apoptosis segment (Fig. 4.1E). Necrotic cell count after 24 h treatment
is not quite high in any conditions, and it is visible only after 48 h exposure to Aβ (25-35).
Similar to cytotoxicity data, 5 µM of Aβ (25-35) can significantly induce the apoptotic cell cycle
after 24 h relative to untreated condition (P=0.026). Representative histograms of cytotoxicity
and apoptosis-necrosis are shown in Fig. 4.1, B and D respectively.
We assured the ability of aggregated Aβ (25-35) to induce apoptosis by measuring
cleavage of native PARP-1 using immuno-blot technique (Fig. 4.1, F and G). Densitometric
analysis (Fig. 4.1G) of the PARP expression revealed that treatment with 1 µM Aβ (25-35) for
24 h clearly can induce apoptotic cycle in SH-SY5Y cells (~25% increase in PARP-1 cleavage
compared to untreated; P=0.0092). This was confirmed by a dense band of the cleaved PARP-1
at 89kD (Fig. 4.1F; third lane from right). These results also support the flow cytometry analysis
performed to detect apoptosis and necrosis in SH-SY5Y cell line. This data supports all the
recent work done in this field to confirm the cytotoxicity of small 11 amino acids long peptide
fragment of beta amyloid11,35.
In 96 well plates based fluorometric DAF FM and DCF-DA assay, we confirmed the
modulation of RNS and ROS level respectively in SHSY-5Y upon 24 h exposure to different
doses of Aβ (25-35) (Fig. 4.1 H-J). In the case of DAF FM based assay, we observed dose
dependent increase of RNS level (Fig. 4.1H, I). Confocal microscopy image confirmed the
intracellular level of RNS production (Fig. 4H) upon different treatment conditions (panel i,
untreated; panel ii, 1µM; panel iii, 10 µM; panel iv, 20 µM Aβ (25-35) treatment respectively).
The increase in the intracellular RNS level is highly significant when untreated and 20 µM Aβ
(25-35) treatment are compared (P=.0573; Fig. 4.1I). Whereas DCF-DA assay data confirmed no
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increase in ROS production even at 50 µM Aβ (25-35) treatment for 24 h in SHSY-5Y cell (Fig.
4.1J; P=0.3612).

It was highly interesting to observe only significant increase in RNS level

when compared to ROS level after Aβ (25-35) treatment under same conditions. As the ROS
data contradict many findings suggested by different research group35,36, DCF-DA assay was
repeated more than ten times which helped to consolidate the result itself.

So, it can be

suggested that excess level of RNS formation lead to the activation of apoptotic cycle in SHSY5Y cell upon Aβ (25-35) treatment.
Role of Aβ (25-35) in Synphilin-1 and α-synuclein aggregation
Failure of the ubiquitin-proteasome system (UPS) that normally degrades misfolded
proteins leads to the formation of so-called aggresomes18,19,37. Proteinaceous aggregates can
induce cytosolic assembly of aggregation-prone soluble proteins through seeding-like
mechanism that share similarities with prion propagation13-16,20,29. Recent findings indicated the
prion-like propagation of Aβ (1-42), demarcated as Aβ aggresome adept of self-propagation
within the brain15,16. The overlapping clinical and pathological features of brain amyloidogenesis
in AD and PD patients gave rise to the speculation of mechanistic connection in between AD and
PD etiology21-24. The major Parkinsonian biomarker α-synuclein is associated with the synthesis
of dopamine neurotransmitter38. Synphilin-1 is a minor Parkinsonian biomarker and the primary
constituent within Lewy neurites along with α-synuclein39. Interestingly, both amyloid beta
fragment and α-synuclein are categorized as amyloidogenic proteins where alpha helix
dominated functional protein transformed into beta sheet dominated rogue protein40. Therefore,
we examined whether Aβ can affect the folding of synphilin-1. In figure 4.2, we analyze the
cross reaction of Aβ (25-35) in aggregation of synphillin-1, α-synuclein.
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Dopaminergic SHSY-5Y cells were transiently transfected or co-transfected (1:1) with
synphillin-1 and/ or α-synuclein containing pEGFP C2 and/ or pCMV6 plasmid respectively
(Fig. 4.2). Expression pattern of synphilin-1 (Fig. 4.2A.ii) and α-synuclein (Fig. 4.2C.ii) in
SHSY-5Y under untreated condition is similar as previously reported by our laboratory19,25. In
contrast, after Aβ (25-35) treatment the SHSY-5Y cell showed increased cytosolic aggregation
(white arrow) of both synphilin-1 (Fig. 4.2A.iv; v; vi) and α-synuclein (Fig. 4.2C.iv; v; vi)
proteins. The expression pattern of these two proteins upon vehicle (20 µl H₂O) treatment did
not differ from the untreated conditions (Fig. 4.2A.iii; Fig. 4.2C.iii) as expected. The fluorescent
intensity of synphilin-1 and α-synuclein under different treatment is plotted in Fig. 4.2B and Fig.
4.2D respectively. In case of fused EGFP-synphilin-1 protein, we did not notice any change in
intensity up to 1 µM Aβ (25-35) treatment relative to untreated condition (P=0.1456). However,
10 µM and 20 µM Aβ (25-35) treatment significantly changed (P=0.0075) the intensity level of
EGFP-synphilin-1 relative to control (Fig. 4.2B). There is notable difference in intensity of
EGFP-synphilin-1 protein upon 1 µM and 10 µM Aβ (25-35) treatment for 24 h (P=0.0466). The
effect of Aβ (25-35) on α-synuclein seems like more dramatic. 1 µM Aβ (25-35) treatment for 24
h significantly increased (P=0.0003) the intensity of α-synuclein protein (Fig. 4.2D).
Interestingly, at 20 µM Aβ (25-35) treatment the maximum intensity of EGFP-synphilin-1 and αsynuclein proteins are 80 a.u. and 120 a.u. respectively. The difference between the intensity of
these two Parkinsonian proteins (~50%) is highly noticeable under the same treatment condition.
It is also evident that cellular interaction increased or clumped together dramatically only in case
of α-synuclein transfected SHSY-5Y cell after Aβ (25-35) treatment (Fig. 4.2C). It can be
interpreted from these data that Aβ (25-35) is more cross-reactive to α-synuclein relative to
EGFP-synphilin-1.
98

Synphilin-1 and α-synuclein are found in Lewy body of PD patient’s brains39,41. To
investigate the effect of Aβ (25-35), we further created the Lewy body like debris by cotransfecting (1:1) synphilin-1 and α-synuclein in SHSY-5Y cell line. pEGFP-synphilin-1 plasmid
(green signal) and pCMV6-α-synuclein plasmid (red signal) was used for this study19. Colocalization of α-synuclein and synphilin-1 was detected in untreated and vehicle (H₂O) treated
cells as evidenced by the presence of the yellow dot pattern (Fig. 4.2E.ii & iii). The yellow color
is the combined signal of the green and red channels (third column of each condition; Fig. 4.2F).
The co-localization of these two proteins is an accepted Lewy body mimics39,41. To determine
the co-localization of synphilin-1 and α-synuclein protein (extreme right column of each
condition; Fig. 4.2F), the Co-localization Colormap plugin of Image J software was used42. The
correlation of a pair of pixels is calculated by normalized mean deviation product (nMDP).
According to nMDP, values for each pixel ranging from -1 to 1, is visualized on a color scale.
Cold colors (towards blue) indicate exclusion of one fluorophore and hot colors (towards red)
represent colocalization of both the fluorophore. The white arrow in each panel indicates the
localization of Lewy body mimic except Figure 4.2E.i (Empty pEGFP and empty pCMV6 vector
transfection in a 1:1 ratio). After 1 µM Aβ (25-35) treatment for 24 h, there was around a two
fold increase in aggregation of synphilin-1 and α-synuclein (when co-expressed) (P=0.0112 &
P=0.0045 respectively) relative to vehicle treatment (Fig. 4.2F). In the bar diagram X-axis
represents treatment conditions and Y-axis depicts fluorescent intensity. This series of
experiments indicate that the increase in the aggregation of co-expressed synphilin-1 and αsynuclein is a function of Aβ (25-35) concentration (P=0.0218 & P=0.0083 respectively).
SHSY-5Y cells with aggregated Lewy body like debris (white arrow) were also counted using
Image J software to interpret the severity of Aβ (25-35) treatment (Supplementary figure 4.2).
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The data was plotted as a bar diagram where Y axis indicate the number of cell with aggresome
(Fig. 4.2G). It clearly showed the adverse effect of Aβ (25-35) treatment on synphilin-1 and αsynuclein folding (P=0.0239; 10 µM Aβ (25-35) treatment relative to untreated condition).
There was around 3.0 fold increase in cell containing the toxic aggresome upon 20 µM Aβ (2535) treatment relative to untreated condition (P=0.0005). All these data suggestive of the cross
reactive nature of Aβ (25-35) peptide fragment.
We also compared the fluorescent intensity level of synphilin-1 “only” and α-synuclein
“only” expression with co-expressed synphilin-1: α-synuclein (1:1) in SHSY-5Y cell under
different treatment conditions (Fig. 4.2H). In Fig. 4.2H.i we plotted the fluorescent intensity of
green channel (pEGFP-synphilin-1) from Fig. 4.2B and Fig. 4.2F. Whereas only the red channel
(α-synuclein) intensity from Fig.4.2D and Fig. 4.2F was plotted in Fig. 4.2H.ii. In both the cases
no difference in intensity were found under untreated condition (P=0.9101 and P=0.3770). A
significant increase in fluorescence was recorded in case of green channel of co-expressed
synphilin-1: α-synuclein (1:1) (Fig. 4.2H.i; P=0.0301) relative to synphilin-1 (when expressed
alone) under 24 h 1 µM Aβ (25-35) treatment. The change in fluorescent signal of red channel of
co-expressed synphilin-1: α-synuclein (1:1) is not significant relative to α-synuclein (when
expressed alone) except 20 µM Aβ (25-35) treatment (P=0.0272). There is consistent significant
increase of GFP tagged synphilin-1 (when co-expressed along with α-synuclein), protein
aggregation relative to GFP tagged synphilin-1 “only” expression, found as a function of Aβ
(25-35) concentration (1 µM, 10 µM, 20 µM vs untreated; P=0.0301, P=0.0480 and P=0.0058
respectively). It is very clear from this data that there is an effect of α-synuclein on synphilin-1
aggregation under the same treatment conditions when expressed together. It is worthy to
mention that coexistence of synphilin-1 and α-synuclein in Lewy body is very common in PD
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patient’s histopathological sample41. We predicted that misfolded α-synuclein synergistically can
increase the aggregation of synphilin-1 as they known to interact with each other in diseased
condition.
Cytoplasmic Aβ (25-35) influence the interaction of α-synuclein and PDI
From the previous set of data the question arises is how Aβ (25-35) influencing the
aggregation of α-synuclein, an amyloidogenic protein. For that purpose Hilyte™ Fluor 488 - Gly
- Ser - Asn - Lys - Gly - Ala - Ile - Ile - Gly - Leu - Met – OH (Aβ (25-35) Hilyte-488®) was
used to monitor the progression in cell culture medium (DMEM:F12). Our data clearly showed
that Aβ (25-35) Hilyte-488® not only going inside the cell it is also interacting with α-synuclein
(cell transiently transfected with pCMV6- α-synuclein plasmid) in a time dependent manner (Fig.
4.3A). For this experiment 500 nM Aβ (25-35) Hilyte-488® was used and confocal images were
taken at different time (0 h, 0.5 h, 3 h, 6 h, 12 h, 18 h and 24 h) after methanol fixation following
previously described immuno-fluorescent protocol. α-synuclein was detected using texas red
conjugated secondary antibody after overnight exposure to primary monoclonal α-synuclein
antibody. The fourth column of each panel was derived from Colocalization Colormap plug-in of
Image J software42. Hot color (towards red; nMDP: +1) indicates the colocalization of two
fluorophore whereas cold color (towards blue; nMDP: -1) showcase only single fluorophore. The
colocalization of Aβ (25-35) Hilyte-488® and synuclein is indicated by white arrow head in third
and fourth column of each panel. Intake of Aβ (25-35) Hilyte-488® peptide (green channel) was
quantified and plotted in a bar graph (Fig. 4.3B). Data showed statistically significant increase in
the uptake of Aβ (25-35) only after 30 min. of exposure (P=0.0011) as well as the interaction
with α-synuclein. It is clear from the experiment that the uptake of Aβ (25-35) is only time
dependent. It is interesting to note that the increased aggregation of Aβ (25-35) Hilyte-488® was
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noticed only in α-synuclein transfected cell but not in non-transfected cell under the same
experimental condition (Supplementary fig. 4.2A). To confirm the internalization of Aβ (25-35)
Hilyte-488®, but not adhesion, we showed the co-localization of this peptide fragment with
mitochondria using Mito Tracker® Red dye (Supplementary fig. 4.2B). Our data comply with
the findings of other research groups on larger peptide fragment Aβ (1-42)43.
Protein di sulfide isomerase, an endoplasmic reticulum (ER) resident chaperone protein,
guide in proper folding of di sulfide mediated proteins32-34,39. Malfunction of PDI also implicated
in different disorder, especially neurodegenerative diseases

19,25,39

. The site of predilection for

PDI is the organelle endoplasmic reticulum32-34. α-synuclein is reported to be found in cell
membrane, cytoplasm as well as mitochondria21,24,32,38. Several studies reported the interaction of
PDI and α-synuclein both in vitro and in vivo and protective nature of PDI against α-synuclein
fibril formation32. PDI is also found to be a part of the neurofibrillary tangles of AD patients and
Lewy body of PD patients41. Hereby we decided to look into the plausible interaction of Aβ (2535) Hilyte-488® and PDI (Fig. 4.3C). Alexa Fluor® 555 conjugated with secondary antibody was
used after monoclonal PDI primary antibody treatment to detect the PDI. 1 µM Aβ (25-35)
Hilyte-488® treated SHSY-5Y cell was methanol fixed and images were taken using LSM 700
microscope. The colocalized pixel scatter plot (inset in the fourth column) and nMDP color
image (fourth column) strongly suggest the colocalization of PDI and Aβ (25-35) Hilyte-488®
(marked by white arrow head). Our previous two data (Fig. 4.3A & C) leads to the speculation
that interaction can be possible between PDI, α-synuclein and Aβ (25-35). To test the hypothesis
we treated the α-synuclein transfected SHSY-5Y cell with different doses of Aβ (25-35) ranging
from 1µM to 20 µM for 24 h under controlled conditions (37ºC and 5% CO₂). To our surprise
there was no colocalization of PDI and α-synuclein protein found in case of non-transfected cell
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under 10 µM Aβ (25-35) treatment and untreated but α-synuclein transfected cell (Fig. 4.3D).
Interestingly the scatter plot and nMDP color map strongly suggest the perinuclear colocalization
of PDI (green channel; Alexa Fluor 488 conjugated secondary antibody) and α-synuclein (red
channel; Texas Red conjugated secondary antibody) when treated with 1µM Aβ (25-35) for 24 h.
When increased the concentration of Aβ (25-35) to 10 µM we found perinuclear as well as
cytoplasmic colocalization (white arrow head) of these two distinctly located proteins. Our
immunoprecipitation assay consolidates the same finding (Fig. 4.3E & F; see method section).
The bar diagram was plotted using Image J software where Y axis represent the α-synuclein /
PDI ratio signal (Fig. 4.3F). Significant increase (P=0.0001) in α-synuclein signal found under 1
µM Aβ (25-35) treatment when compared with the untreated condition. There was also dose
dependent increase in α-synuclein signal recorded (P=0.0071; 1 µM vs 10 µM). Recent finding
suggests the activity and subcellular redistribution of PDI is strongly correlated with the ER
stress as well as its s-nitrosylation status31. So, Aβ (25-35) mediated α-synuclein and synphilin-1
aggregation might cause the ER stress which in turn forced the redistribution PDI. Cytoplasmic
PDI then become available for the interaction with α-synuclein.
Consequences of Aβ (25-35) induced S-nitrosylation of PDI
Our previous data (Fig. 4.1H & I) showed excessive increased level of RNS upon Aβ
(25-35) treatment. Previous study indicates a strong relation between excess cytoplasmic RNS
and post-translational modification of PDI19. Reactive NO• radical can readily oxidize the labile
thiol (-SH) group of cysteine amino acid of PDI39. Many group including us also suggested the
influence of S-nitrosylated PDI on misfolding of major and minor Parkinsonian protein33,39.
SNO-PDI is also implicated on the ER-stress mediated activation of apoptotic pathway19,33. To
investigate the role of excess cytosolic RNS on the chaperone PDI, we performed the
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immunoprecipitation assay (Fig. 4.4A & B). Equal amount of cell lysate after different treatment
was pulled down using anti-PDI and then immunoblotted with SNO-Cys-BSA antibody and antiPDI antibody19. The protein signal was quantified using Image J software and plotted as bar
diagram (Fig. 4.4B). We found significant increase in SNO-Cys-BSA signal around 57 kD
molecular weight, indicative of SNO-PDI, when treated with 1 µM Aβ (25-35) compared to
untreated condition (P=0.0174). We also confirmed dose dependent (1 µM vs. 10 µM Aβ (25-35)
treatment; P=0.0229) increase in SNO-PDI level. We further checked heat shock protein (HSP)
70 level and PDI as an indicator of ER stress (Figure 4.4C). There was substantial increase in
the expression level of both HSP 70 and PDI after 24 h Aβ (25-35) treatment (1 µM, 10 µM, 20
µM and 50 µM). Data suggests major increase (P=0.0028; 1 µM vs. untreated) in HSP 70 level
(white box; Fig. 4.4D) whereas the same trend noticed in PDI expression level (grey box; Fig.
4.4D) only after 10 µM Aβ (25-35) exposure (P=0.0304; relative to untreated condition).
Progressive decrease in dopamine level is a major concern in PD patients38. Tyrosine
hydroxylase (TH) enzyme plays a major role dopamine synthesis from the amino acid tyrosine38.
So we decided to check the TH level in dopaminergic SHSY-5Y cell line after Aβ (25-35)
treatment (Fig. 4.4C; second row). To our surprise dose dependent increase in TH level was
recorded, which does not comply with the normal notion of dopamine chemistry in PD patients.
It might be possible that the problem lies in dopamine secretion but not the production44.
Significant increase in TH expression (black box) was graphed in bar diagram (P=0.0075; 1 µM
vs. untreated; Fig.4.4D). GAPDH was used as a loading control.
Misfolded non-functional proteins are tagged by ubiquitin to guide them for proteosomal
degradation for maintaining of cellular homeostasis18. The upper limit of this ubiquitin
proteasome system (UPS) is very critical between cell survival and controlled death18,20.
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Whenever the ubiquitinated protein aggregates reach beyond the level of tolerance (failure of
UPS system) the cell activates cascades of event leading to apoptosis18-20,29,35. In light of the
previous discussed results, I decided to check the aggregated cytosolic protein load under
different Aβ (25-35) treatment (Fig. 4.4E & F). We separated the insoluble protein fraction and
ran in 12% SDS-PAGE gel. Gradual increase in the signal of ubiquitinated protein aggregates
was graphed in the bar diagram as a function of Aβ (25-35) concentration (Fig. 4.4E). Nearly
two folds increase in accumulated ubiquitinated protein was found after 20 µM Aβ (25-35)
treatment when compared against the untreated condition (P=0.0222). These set of analysis
strongly suggest a strong correlation between the posttranslational modification of PDI, ER
stress, accumulation of ubiquitinated proteins and cell death.
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4.4 Conclusion
In this study we have investigated the effect of 11 mer peptide fragment, amyloid beta
(25-35) which considered as the functional domain of amyloid beta (1-42)9-11. A beta was found
to have a high toxicity on the neuronal and neuroblastoma cell line16. We showed that Amyloid
beta (25-35) aggregates have the potential to activate the apoptotic pathway in SH-SY5Y cell as
evidenced by PARP-1 cleavage and Annexin V-FITC, both used as apoptotic marker. Our data
indicate the excessive cytosolic RNS production as a function of Aβ (25-35) treatment leading to
S-nitrosylation of protein disulfide isomerase. This set of work also suggests that Aβ (25-35)
aggregates not only cross the cell membrane but also can initiate aggregation of GFP tagged
synphilin-1 as well as α-synuclein whether expressed separately or combined in SH-SY5Y cell
line. Time lapse study clearly showed strong interaction of probed Aβ (25-35) with α-synuclein
and PDI. Here for the first time we reported the interaction of PDI and α-synuclein as a function
of Aβ (25-35) treatment. It can be suggested that ER stress and posttranslational modification of
PDI make it cytosolic to interact with α-synuclein and Aβ (25-35).
In

conclusion,

our

results

advance

the

understanding

of

the

intricacy

of

neurodegeneration field by mapping putative mechanism behind the failure of cellular
housekeeping machinery but also a plausible explanation of overlapping histopathological
findings in neurodegenerative diseases. The reported results can further research in related
neuropathies whose onset may be related to the dysfunction of the cellular homeostasis
apparatus. The current report can be used for developing preventative approach against the
disease.
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Fig. 4.0. Proposed mechanism of Aβ (25-35) induced formation of Lewy body inclusion which
resulted in Er stress mediated cell death.
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Figure 4.1. RNS dependent activation of apoptotic pathway upon Aβ (25-35) treatment. Fig. (A)
Dynamic Light Scattering of Aβ (25-35) showing aggregation. Panel (B) showing the cytotoxic
effect upon different concentrations of beta-amyloid (25-35) treatment (48 hrs) on SH-SY5Y
cells, staining them with PI and further quantitated using the flow cytometry shown in histogram
108

Fig. (C). (D) Detection of cellular apoptosis/ necrosis in SH-SY5Y cells induced by betaamyloid (25-35) treatment. Cells were treated with beta-amyloid for 24 hrs duration followed by
staining with annexin-V FITC (apoptotic marker) and PI (necrotic marker) mixture for 15
minutes on ice in the dark. Afterwards the percentage (Fig. 4.1A) of apoptotic and necrotic cell
population was quantitated using a flow cytometer. The histogram is shown in panel (E). (F)
Effect of Aβ (25-35) induced poly (ADP-ribose) polymerase (PARP) cleavage, hallmark of
apoptosis progression, in SH-SY5Y cells. (G) PARP-1 cleavage bands were densitometrically
analyzed via Western blot analysis using Image J software. DAF-FM fluorescence image was
taken using LSM700 confocal microscope to detect intracellular RNS (H) and was quantified (I)
by Fluoroskan software in 96 well format after 24 h Aβ (25-35) treatment. Reactive oxygen
species (ROS) level was detected using DCF-DA dye after 24 h exposure to Aβ (25-35) in
SHSY-5Y cell line (J). Each experimental point was assessed in triplicate or more. Statistical
significance comparing two groups are illustrated as P value.
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Figure 4.2. Aβ (25-35) induced Lewy body-like inclusions formation in SH-SY5Y cells.
Transfected SHSY5Y cells were untreated or stressed with Aβ (25-35) for 24 h. Panel (A)
confocal fluorescence images of SH-SY5Y cells reveal the presence of cytoplasmic aggregates in
cells transfected with EGFP or EGFP-tagged synphilin-1 plasmid. Panel (C) fluorescence images
of SH-SY5Y cells revealed the presence of α-synuclein cytoplasmic aggregates under different
conditions. (E) Cells transfected with α-synuclein: synphilin-1 (1:1) and then treated under
different conditions. Figure 4.2 (A; C; E) (i) cells transfected with pEGFP-C2 empty vector and /
or pCMV6 empty vector; (ii) cells untreated but transfected with Synphilin-1 and / or αsynuclein; (iii) treated with distilled water; (iv, v, vi) Cells treated with different concentration
of Aβ (25-35) for 24h alone; All the cells were counterstained with DAPI to stain the nucleus
(blue color). White arrows indicate the presence of aggregates. Synphilin-1 was tagged with GFP
showing green color and α-synuclein is shown in red color. Yellow color represents colocalization of α-synuclein and synphilin-1 (white arrow). Colocalization Colormap plug-in of
Image J software used to find the colocalization as indicated by nMDP color scale ranging from
(-)1 to (+)1. Each scale bar represents 10 µm. Panel (B; D) Quantification of synphilin-1 (Green
Channel) and α-synuclein expression (Red Channel) in SHSY-5Y cell line upon different
treatment. (F) Quantification of total co-localized aggregates (mimic of Lewy body) in αsynuclein and synphilin-1 co-transfected SHSY-5Y cell treated with different conditions. (G)
Total number of SH-SY5Y cells showing Lewy body-like aggregation upon Aβ (25-35)
exposure (n= 200; Supplementary Figure 1). (H) Comparative quantitative study of individual
expression and co-expression of Synphilin-1 (i) and α-synuclein (ii) upon treatment at different
Aβ (25-35) concentrations. Statistical significance compared with untreated are illustrated as P
value (n= 100). All the quantitative analysis was done using Image J software from n=100 cells
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indicated as mean ± S.D. Y-axis represents the fluorescence intensity and X-axis represents 24 h.
treatment conditions. Region of Interest (ROI) was 400 pixels (20x20). S.S illustrated as P value.

Fig. 4.3. Spatiotemporal dependence of Aβ (25-35) induced PDI and α-synuclein
interaction. Time dependent interaction of Aβ (25-35) Hilyte-488® (Green channel) with αsynuclein (Red channel) showed perinuclear localization of both proteins after 24 h in SHSY-5Y
cell line (A). Fluorescent intensity of green channel quantified to assess the uptake the Aβ (25112

35) Hilyte-488® by SHSY-5Y as a function of time (B). Colocalization (Yellow in third column
and red in fourth column; white arrow head) of PDI (Green) with α-synuclein (Red) upon Aβ
(25-35) treatment was imaged using fluorescent microscopy (C). Equal amount of cell lysate
after 24 h Aβ (25-35) treatment were ran in 12% SDS-PAGE gel after immunoprecipitated by
PDI then blotted proteins detected using α-synuclein primary antibody (D) and quantified by
Image J software (E). Each fourth column of image (Red indicates colocalization) as well as
inset of scatter plot was processed by Image J software (A; C). Colocalization Colormap plug-in
of Image J software used to find the colocalization as indicated by nMDP color scale ranging
from (-)1 to (+)1. Each scale bar represents 10 µm. Statistical significance annotated as P value
(n=3).
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Fig. 4.4. Cellular impact on Aβ (25-35) treatment. S-nitrosylation of PDI in Aβ (25-35) treated
SHSY-5Y cell line detected by immunoprecipitation (A) and quantified (B). Aβ (25-35) induced
over-expression of heat shock protein 70 (HSP70), an ER-stress marker protein (C). Level of
tyrosine hydroxylase (TH), PDI and GAPDH expression detected using respective antibodies (C)
and quantified (D). Aβ (25-35) induced accumulation of ubiquitinated proteins in the insoluble
fraction of cell lysate detected using ubiquitin primary antibody (E) and quantified (F). Equal
amount of protein (10 µg/ well) was loaded for each condition. GAPDH was used as a loading
control. Western Blots signals were densitometrically quantified using Image J software from
three independent tests indicated as mean ±S.D. Statistical significance among pairs of samples
is annotated as P value (n=3).
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Supplementary Figure

Supplementary Figure 4.1. Co-localized aggregates (mimic of Lewy body) of α-synuclein and
synphilin-1 (1:1) expressed in SHSY-5Y cells under Aβ (25-35) treatment. Transfected SHSY5Y cells were untreated or stressed with different treatments. Cells transfected with α-synuclein
and synphilin-1 without any treatment (i); cells treated with 1 µM, 10 µM, 20 µM Aβ (25-35)
respectively for 24 h (ii, iii, iv). All the cells were counterstained with DAPI to delimitate the
nucleus (Blue color).. Synphilin-1 was tagged with GFP showing green color and α-synuclein is
shown in red color. Yellow color represents co- localization of α-synuclein and synphilin-1.
Extreme right panel of each figure represents the co-localization of α-synuclein and synphilin-1
(white spot) whereas yellow arrows indicate the presence of aggregates determined using Image
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J co-localization software (n=200). The scale bar represents 50 µm. Each experiment was
repeated in triplicate

Supplementary Figure 4.2. Internalization of Aβ (25-35) Hilyte-488® after 24 h treatment in
SHSY-5Y cell. SHSY-5Y cell harvested in DMEM: F12 medium under proper condition after
500 nM Aβ (25-35) Hilyte-488® (green channel) treatment (A). To prove that Aβ (25-35)
Hilyte-488® is going inside the cell (not adhesion with plasma membrane), we stain the
mitochondria using Mito Tracker® Red (B). Colocalization with mitochondria confirmed the
internalization of Aβ (25-35). Second column bottom image (Red indicates colocalization; white
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arrow head) as well as inset of scatter plot was processed by Image J software (B).
Colocalization Colormap plug-in of Image J software used to find the colocalization as indicated
by nMDP color scale ranging from (-)1 to (+)1. Each scale bar represents 10 µm.

Supplementary Figure 4.3. Supportive gel for Figure 4.4A (A) and supportive information for
Figure 4.3E (B).
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Chapter 5:
Overall discussion and concluding remarks
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5.1 Overall discussion and concluding remarks
The overall studies in this dissertation have been done using dopaminergic neuroblastoma cell
line SHSY-5Y and PC12. First we created a toxin induced Parkinsonian cell model to mimic the
environmental stress conditions on neuronal cell. Rotenone and MPTP were used as ER stressor,
the known toxic compounds found to be evidence for Parkinsonian symtoms when exposed to
human1. Looking for the lead compounds against free radical stress, we tested the
neuroprotective effect of Na-D-β-hydroxybutyrate (NaβHB), ellagic acid (EA), piperine and
EF24 against rotenone toxicity by using SH-SY5Y or PC12 cells. Pretreatment of cells with
NaβHB and EA provided significant protection relative to EF24 and piperine to SHSY5Y cells.
NaβHB and EA also found to attenuate the rotenone-induced activation of native PARP-1
protein. The dietary small molecule EA can also scavenge the rotenone induced reactive oxygen
and recative nitrogen species thus inhibits posttranslational modification of PDI. We concluded
that the healthy PDI hinder the Lewy body like inclusion formation as well as apoptotic cell
death. Major and minor constituents of Lewy body are α-synuclein and synphilin-1 respectively.
We have created cytoplasmic Lewy body mimic inside dopaminergic cell by co-transfecting αsynuclein and synphilin-1 (1:1). Our data suggest that rotenone can increase these Lewy bodylike inclusions significantly due to excessive production of reactive oxygen and nitrogen species.
Pretreatment of EA (6 h prior to rotenone treatment) is protective against rotenone induced
increased production of Lewy body inclusions. It is clear from our findings that maintaining
healthy PDI would be the key to find the cure of neurodegenerative disese. Studied small
molecules NaβHB and EA can be a good scaffold to build on agaist reactive species mediated
neuronal cell death.
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Overlapping pathological and clinical symtoms of many neurodegenerative diseases has
always baffeled the scientist community to find the exact etiology2-4. It is belived that a common
mechanism lies behind all these neurodegenerative disorders3,4. Designing of a pharmacophore
can be achieved if we can understand the molecular mechanism of behind aggregation of
proteins associated with neurodegenerative diseases i.e. PD, AD, LBV, AD-LBV etc. We have
decided to address the question using simple Parkinsonian cell model where we selectively
expressed or co-expressed synuclein and synphilin-1 protein. We found the 11-mer functional
domain of amyloid beta (1-42), Aβ (25-35), can induce aggregation of amyloidogenic proteins.
Aβ (25-35) mediated s-nitrosylation of PDI lead to cellular toxicity by hampering the ER
homeostasis as well as aggravated the Lewy body like inclusion formation in dopaminergic
SHSY-5Y cell line.
Our study suggests that the posttranlational modification of PDI due to excessive free
radicals is one of the major concerns for neuronal cell death. Whereas dietary small molecules
have the potential to deter the reactive species therefore can be used as therapeutic scaffold
against neurodegenerative diseases.
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5.2 Future direction
Chronic exposure of environmental toxins (rotenone, MPTP etc.) can lead to neuronal
cell death through elevated free radical stress. Failure of mitochondrial electron transfer chain to
produce ATP can lead to endoplasmic stress as well as the ATP dependent activation of UPS1.
Our study indicates that utilization of ketone body can surpass the consequences of
mitochondrial complex I inhibitors. Ketogenic diets are often encouraged by physician to correct
cellular metabolism anomalies, loose extra fat, increasd brain activity also believed to detarr the
possibilities of AD and PD1. A long term study of ketone bodies on toxic induced Parkinsonian
in vivo model would be very fruitful to understand the mechanism in detail.
Ellagic acid, a polyphenolic fruit derived small molecule, is found to be effective against
both ROS and RNS from our study. It also can protect the PDI from nitrosative insult thus can
alleviate the ER stress and protein aggregation induced cell death. As this small molecule can
cross the blood brain barrier, it will be very interesting to investigate the effect of EA in toxin
induced PD in vivo model. As we nonstop looking at various other small molecules we found
ferristatin analogues as well as monocurcumin to be very promising against ROS and RNS from
our initial screening. We also created a stable α-synuclein-SHSY-5Y cell line for further studies.
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Fig. 5.1. Stable α-synuclein-SHSY-5Y (α-syn-SHSY-5Y) created after G418 (900 µg/ml)
selection. Typical α-synuclein expression is shown using specific primary α-synuclein antibody
(A). Texas red conjugated seconady anibody (red channel) used to detect the expression by
confocal microscope Zen LSM 700. Again primary α-synuclein antibody was used to qualify αsynuclein by Immunoblot technique (B). C terminal MYC/DDK tagged α-synuclein inserted in
pCMV6 vector was used. The 19 kDa and 38 kDa molecular weight is suggestive of monomer
and dimer of α-synuclein protein expressed in SHSY-5Y cell.

Fig. 5.2. Cytotoxicity of Fer-1 on SHSY-5Y. Bright field image of SHSY-5Y upon different
treatment condition for 24 h (A). Propidium Iodide and Hoechst based high throughput screening
assay for cytotoxicity study of fer-1 compound at different concentration (B).

122

Fig. 5.3. Anti-apoptotic ability of Fer-1 through maintaining endoplasmic reticulum (ER) and iNOS homeostasis. Immunoblot technique was used to detect the apoptotic activation: vehicle
control (DMSO), Fer-1, rotenone and pretreatment with Fer-1 and then 24 h rotenone exposure
(A). Rotenone (RT) induced over expression of heat shock protein 70 (HSP70) is mitigated by 1
µM Fer-1 pre-treatment (A). Expression of ER-stress marker protein, HSP70, is quantified under
different treatment using Image J (B). RT induced over expression of i-NOS is inhibited by 1 µM
Fer-1 pre-treatment (C). Quantification of i-NOS expressions, after GAPDH normalization,
using Image J (D). Statistical significance between samples is illustrated as P-value (n=3).
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Figure 5.4. Role of Fer-1 in α-synuclein aggregation in α-syn-SHSY-5Y cell. Cells transfected
with pCMV6 empty vector, untreated α-syn-SHSY-5Y cells, treated with DMSO 0.02% v/v,
treated with 1 µM Fer-1, cells exposed to rotenone (RT) (500 nM) for 24 h alone and cells
treated with 1 µM Fer-1 for 4 h prior exposed to rotenone (500 nM) for 24 h are the different
conditions used for this study (A, B). Confocal fluorescence images of SHSY-5Y cells after
100% methanol fixation revealed the presence of α-synuclein cytoplasmic aggregates under
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different conditions (A). All the cells were counterstained with DAPI to stain the nucleus (blue
color). White arrow head indicates aggregation of α-synuclein protein. Black arrow is
representative of vesicle shown in DIC image. Quantification of α-synuclein (Red channel) in
SHSY-5Y cell line upon different treatment using Image J software from n=200 cells indicated
as mean ± S.D (B). Statistical significance between pairs of samples is illustrated as P-value.
Each scale bar represents 10µm. Each experiment was assessed in triplicate.
Our study on cross reaction of Aβ (25-35) ensures the importance of PDI in neuronal cell.
As a future direction we are looking at dirrerent small molecules like myrecetin, monocurcumin
along with EF24, 31 curcumin analogues, ellagic acid to intervene the β sheet stacking of
amyloid beta fragment. Monocurcumin compound came out as the most promising candidate
from our primary screening. It also can be promising in drug designing if we can replicate our
findings in AD-LBV rat model.
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Fig. 5.5. Thioflavin T (ThT) fluorophore based spectroflurometric assay showed different
fluroscence profile of treated or untreated Aβ (25-35). X-axis represents time in seconds and Yaxis depicts the fluorescent intensity.

Fig. 5.6. Cytoxicity of monocurumin on SHSY-5Y cell. Different concentration of
monocurcumin was used as treatment for 24 h on SHSY-5Y cell. Highthroughput screening was
employed using propidium iodide a necrotic cell marker where as Hoechst used as total cell
count.
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